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Abstract
Background: Anxiety is a prevalent problem frequently presenting in the primary care setting
in the United States. The lack of routine anxiety screening and evidence-based treatment
protocols in the adult primary care setting causes physical, social, and economic consequences.
Purpose: The purpose of this Doctor of Nursing Practice (DNP) evidence-based practice (EBP)
quality improvement project was to implement an EBP anxiety screening and treatment protocol
for adults in a primary care clinic to increase early identification and improve management of
generalized anxiety disorder (GAD).
Theoretical Framework: W. Edwards Deming’s Plan-Do-Study-Act (PDSA) cycle framework
was utilized for this project. The PDSA outlines the necessary cycles of how to effectively
identify, develop, implement, analyze, and sustain quality improvement practice changes in an
organization.
Methods: Descriptive statistics and Pearson’s r were used for this retrospective/prospective
chart review design.
Results: Findings are clinically significant and demonstrate 69.07% of post-implementation
prospective charts utilized the generalized anxiety disorder 7-item (GAD-7) screening tool to
screen for GAD, which quantified an anxiety level, and can be utilized to prescribe EBP
treatment for adults with GAD in primary care.
Conclusion: Although findings of anxiety score correlating to EBP treatment were statistically
insignificant, further studies are necessary to determine if obtaining an anxiety level results in the
provider making changes to preexisting treatment plans that align with EBP treatment in adults
with GAD.
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Chapter One: Nature of Project and Problem Identification
Evidence-based practice (EBP), which is a synthesis of best practices, clinician expertise,
and patient preferences and values, ensures the provision of patient care excellence and improves
patient outcomes (Melnyk & Fineout-Overholt, 2015). Best practices recommend screening
adults for generalized anxiety disorder (GAD) in primary care, with a screening tool that
quantifies anxiety levels and correlating the level to prescribing treatment. Anxiety treatment
interventions such as specific selective serotonin re-uptake inhibitors (SSRIs), specific selective
norepinephrine re-uptake inhibitors (SNRIs), mental health referrals, and psychotherapy are
effective and approved by the United States (U.S.) Federal Drug Administration (FDA) for the
treatment of GAD (Abejuela & Osser, 2016; Craske & Bystritsky, 2017; Locke, Kirst, & Shultz,
2015; National Institute for Health and Care Excellence [NICE], 2011; National Institute of
Mental Health [NIMH], 2016). A primary care practice lacked consistent, uniform use of a GAD
anxiety screening tool and treatment protocol to routinely screen and treat patients with GAD
according to best practices. A review of the literature illuminated EBP protocols for screening
and treating patients with GAD. Implementation of an EBP GAD screening and treatment
protocol in primary care can result in timely and accurate diagnosis and appropriate anxiety
treatment, improving the quality of life in adults with GAD (Locke et al., 2015; NICE, 2011;
NIMH, 2016; Spitzer, Kroenke, Williams, & Lowe, 2006; Stein & Sareen, 2015).
Background Information
The Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) informs
that anxiety is a term used to describe inappropriate worry or fear that is associated with
anticipating an upcoming threat (American Psychiatric Association [APA], 2013). Anxiety
induces more than necessary emotions of fear or worry not attributable to an occasional life
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experience that is expected to induce anxiety (APA, 2013; NIMH, 2016; Waters et al., 2015).
Anxiety can cause a decrease in quality of life related to disruption in sleep quality and patterns,
headaches, gastrointestinal problems, muscle tension, restlessness, irritability, chronic fatigue,
and the inability to concentrate and control worry or fear (Edmund & Sheppard, 2018; Locke et
al., 2015; NIMH, 2018). Mental unease and physical stress related to anxiety also contribute to
avoidance behaviors and a decrease in quality of life (Waters et al., 2015). GAD is one subset of
anxiety. GAD is distinguished by experiencing more than necessary and difficult to control
feelings of anxiety, worry, or fear causing significant impairment and peril occurring more days
than not for a minimum of 6 months (Craske & Bystritsky, 2017; Stein & Sareen, 2015).
GAD is considered a chronic condition (Stein & Sareen, 2015). Symptoms of GAD may
be experienced intermittently or constantly and last for a short duration or a lifetime (NIMH,
2017a). The symptoms can range from mild to severe (Spitzer et al., 2006). GAD is not a panic
attack (APA, 2013; Locke et al., 2015). Symptoms of GAD may, however, induce a panic
attack, which is characterized by acute, intense physical symptoms of diaphoresis, chest
tightness, tachycardia, and tachypnea that are results of the activation of the autonomic nervous
system (APA, 2013).
Research is exploring the pathophysiology of anxiety and affirming various theories of
anxiety etiology. Evidence has suggested that anxiety may be attributed to genetics and
disturbances of the neural pathways (APA, 2013; NIMH, 2016). Richards (2018) reported that
learned processes also change the dynamics of the neural pathways. Learned processes that
contributed to the exacerbation of GAD were attentional bias of threat, conditioning, tendencies
toward defensive hyperarousal states, and stress (Nikolic, Aktar, Bogels, Colonnesi, & De Vente,
2018; Simpson, 2012). According to Richards (2018), neural pathways utilize the neurochemical
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hormones cortisol and adrenaline, which are released during states of anxiety and change the
mechanism of action of the nervous system. Neurochemical and learned processes also change
the velocity at which sensory information moves through synaptic gaps, leading to the responses
experienced in anxiety (Richards, 2018).
Disposition to defensive hyperarousal and perceived stressful situations also contribute to
anxiety (Nikolic et al., 2018). An individual with GAD anticipates a perceived threat that leads
to aroused awareness, muscular tension, and avoidance behaviors (APA, 2013). Feelings of
discontentment, apprehension, worry, and/or fear, associated with anxiety, can affect daily life,
resulting in physical, social, and economic consequences (Abejuela & Osser, 2016; Waters et al.,
2015).
Significance of Problem
Presently, 615 million individuals worldwide are diagnosed with depression and anxiety
disorders (World Health Organization [WHO], 2016). Anxiety is nondiscriminatory, and onset
can begin at any age (Essau, Lewinsohn, Lim, Ho, & Rohde, 2018). The NIMH (2017a)
reported that the National Comorbidity Study Replication (NCS-R) found 18.1% of adults in the
United States have experienced an anxiety disorder within the past year. The study found 2.7%
of these anxiety diagnoses are specifically GAD (NIMH, 2017b). Lifetime prevalence of GAD
for individuals aged 18-64 years is estimated at 7.7% for women and 4.6% for men (Edmund &
Sheppard, 2018).
Accurate and prompt diagnosis of GAD in primary care is suboptimal, even though the
Generalized Anxiety Disorder 7-item (GAD-7) screening tool is available for screening and
effectively and accurately diagnoses GAD in primary care patients (Jordan, Mora, & Lowe,
2017; Locke et al., 2015; Roberge et al., 2015; Spitzer et al., 2006). Implementation of
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appropriate EBP treatment for GAD in primary care is also lacking (Roberge et al., 2015).
Benzodiazepines are often used inappropriately for long-term GAD symptom control (Daoud,
Hamburg, Sharma, & Blevins, 2018; Furbish et al., 2017; Song et al., 2017). Best practice
treatments for GAD that have been proven effective for long-term symptom control include
lifestyle modifications, SSRIs, SNRIs, mental health referrals, and psychotherapy (Locke et al.,
2015; NICE, 2011). GAD is not without consequences. The physical, social, and economic
consequences of GAD are substantial and prevalent.
Physical Consequences of GAD
Physical consequences of GAD include an array of subjective complaints and other
mental health ailments. The physical consequences of anxiety include disruption in sleep quality
and patterns, headaches, gastrointestinal problems, muscle tension, restlessness, easy irritability,
chronic fatigue, and inability to concentrate and control worry or fear (Edmund & Sheppard,
2018; Locke et al., 2015; NIMH, 2018). Gastrointestinal distress and headaches are the most
common presenting symptoms of GAD in the primary care setting (Stein et al., 2005).
Individuals with GAD are at a greater risk for self-harming behaviors and attempting suicide
(Bentley et al., 2016; Stein & Sareen, 2015). Anxiety often precedes the development of cooccurring depression (Adams, Balbuena, Meng, & Asmundson, 2016).
Social Consequences of GAD
GAD can cause debilitating impairments that negatively impact daily functioning,
relationships, and job productivity and can lead to substance use. The Sheehan Disability Scale
examined the level of impairment in adults with anxiety disorders and found that 22.8% of
affected individuals experienced serious impairment, 33.7% moderate impairment, and 43.5%
mild impairment, respectively (NIMH, 2017a). A study conducted by Robinson, Sareen, Cox
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and Bolton (2011) found roughly 35% of individuals with GAD utilized drugs and alcohol to
control their symptoms (as cited in Stein & Sareen, 2015). Individuals with GAD may avoid
circumstances or triggers that cause symptoms of physical and mental unease. The symptoms of
mental unease and physical stress related to anxiety are contributory to avoidance behaviors and
decreases quality of life (Waters et al., 2015). Conditioning to use dysfunctional coping
mechanisms like avoidance behaviors can result in dysfunctional personal relationships and job
performance issues.
Economic Burden of Anxiety
Anxiety disorders negatively impact finances and increase healthcare costs. In 2013,
nearly $49 billion was spent in the United States on anxiety-related healthcare expenses
(Shirneshan, 2013). Direct healthcare expenses including pharmacological treatment, inpatient
services, and outpatient services accounted for $33.71 billion of the nearly $49 billion, while
indirect expenses for morbidity-related expenses cost $12.72 billion, and mortality expenses cost
$2.34 billion (Shirneshan, 2013). Mental health issues have a negative financial impact because
of loss of job productivity secondary to absenteeism (Madan, Henderson, Hashtroudi, Hope, &
Harvey, 2013). Untreated anxiety leads to physical symptoms that result in individuals missing
work (Madan, Henderson, Hashtroudi, Hope, & Harvey, 2013). The WHO (2019) estimates that
anxiety disorders are responsible for a global $1 trillion loss in productivity.
Misuse of Benzodiazepines
Short-acting rescue medications, such as benzodiazepines, are pharmacologically
designed to rapidly reduce severe anxiety symptoms such as those experienced during a panic
attack and should only be prescribed for a short-term basis to augment treatment (Locke et al.,
2015; NICE, 2011). Commonly, patients and healthcare providers pursue anxiety rescue
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medications to manage anxiety symptoms (Furbish et al., 2017; Song et al., 2017). Despite
evidence that long-term treatment of GAD typically can be achieved with SSRIs and/or CBT,
healthcare providers and patients often default to the misuse of benzodiazepines (Wetherell et al.,
2013).
The prescribing and dosages of benzodiazepines have increased over the last 20 years
(Lowry, 2016). Oftentimes, GAD is maltreated with untimely, inappropriate, or persistent use of
benzodiazepines (Furbish et al., 2017). Benzodiazepines are regularly substituted as long-term
anxiety medication therapy, which has proven to be ineffective for this purpose (Song et al.,
2017). A study about benzodiazepine use for anxiety by Swift and Charles (2016) revealed 60%
of participants had benzodiazepines prescribed for more than 5 years (as cited in Lowry, 2016).
Swift and Charles (2016) found individuals who were prescribed benzodiazepines pro re nata
(PRN) had an increased risk for misuse of the medication and often took the medication
regularly (as cited in Lowry, 2016).
Consistent misuse of benzodiazepines promotes physical dependence and can produce
adverse health effects when benzodiazepines are abruptly discontinued (Song et al., 2017).
Withdrawal syndrome from benzodiazepines includes symptoms such as confusion, sleep
disturbances, irritability, anxiety, psychosis, delirium, seizure activity, and hyperadrenergic
conditions (Gresham, 2018). Mortality rates related to benzodiazepine overdose have also
increased. Mortality rates related to benzodiazepine misuse for 2016 was reported at 10,684
(National Institute on Drug Abuse, 2018). Long-term GAD symptom control cannot be achieved
without alternative and appropriate interventions like antidepressant medications and/or CBT
(Locke et al., 2015; Song et al., 2017). Ultimately, the avoidance of the misuse of
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benzodiazepines for long-term GAD symptom control is essential for enhancing quality of life in
adults with GAD (Furbish et al., 2017; Locke et al., 2015; NICE, 2011; Song et al., 2017).
Lack of Consistent GAD Diagnosis and Appropriate Treatment in Primary Care
Accurate assessment, diagnosis, and appropriate anxiety treatment are essential to ensure
appropriate long-term outcomes for individuals with GAD. Oftentimes, individuals experiencing
symptoms of GAD seek medical intervention from their primary care provider who may be the
sole healthcare team member who manages an individual’s feelings of anxiety associated with
GAD (Goldberg et al., 2016; Jordan et al., 2017; Weisberg, Beard, Moitra, Dyck, & Keller,
2014; Wiegner, Hange, Bjorkelund, & Ahlborg, 2015). As a result, the initial diagnosis and
management of anxiety are often performed by the primary care provider. Accurate and timely
recognition of GAD in the primary care setting is lacking (Roberge et al., 2015).
Further, the management of GAD lacks consistent, routine use of an appropriate
evidence-based treatment algorithm to assist in long-term anxiety symptom control (Roberge et
al., 2015). Currently, only 36.9% of individuals presenting with anxiety are receiving treatment
(NIMH, 2017a). Of that treated population, 34.3% of individuals’ treatment plans are considered
barely adequate (NIMH, 2017a). Pharmacological management of anxiety can be provided by a
primary care provider (Locke et al., 2015; NIMH 2018). Primary care providers can diagnose
and manage anxiety; however, psychotherapy or individuals who require more complicated
pharmacological interventions should be referred to a mental health specialist (Abejuela &
Osser, 2016; Locke et al., 2015; NICE, 2011; Stein & Sareen, 2015).
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Problem Statement
An adult primary care medical practice lacked consistent, uniform use of a GAD anxiety
screening tool and implementation of evidence-based clinical practice guidelines for anxiety
treatment.
Purpose Statement
The purpose of this quality improvement project was to implement an EBP anxiety
screening and treatment protocol for adults in a primary care clinic to increase early
identification and improve management of GAD.
Plan-Do-Study-Act Theoretical Framework
W. Edwards Deming developed the Plan-Do-Study-Act (PDSA) in 1993. The W.
Edwards Deming Institute (2019) explains that Deming believes that in organizational change,
new knowledge is acquired from learning. Deming developed the PDSA theory for
improvement process changes to predict the outcome of an improvement project, analyze the
actual outcome of the implemented improvement project, and then study the comparison of the
predicted outcome to the actual outcome (The W. Edwards Deming Institute, 2019). Through
this process, new knowledge is learned and then, if warranted, adjustments to the improvement
project can be made for sustainability (The W. Edwards Deming Institute, 2019). The W.
Edwards Deming Institute (2019) explained the PDSA as a systematic process that can be
utilized for the acquisition of knowledge needed for sustainable improvement of a service,
product, or process.
The PDSA is an effective model for guiding quality improvement changes. The Institute
for Healthcare Improvement (IHI) and the U.S. Department of Health and Human Services:
Agency for Healthcare Research and Quality (AHRQ, 2015) provide succinct information about
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how to utilize the PDSA in practice. The AHRQ (2015) stated that the PDSA is a simplistic
method that can assist in the development and evaluation of a process improvement plan in
healthcare. According to the IHI (2019), the PDSA has been implemented in hundreds of
healthcare institutions. A worksheet was developed by the IHI to help organizations to develop
and test a system change using the PDSA. The AHRQ (2015) outlined the necessary phases of
how to effectively identify, develop, implement, analyze, and sustain quality improvement
practice changes in an organization using the PDSA model. The PDSA model is divided into
cycles that guide each aspect of developing, implementing, and analyzing quality improvement
changes to achieve sustainability.
Theoretical Framework Concepts and Application to Project
This EBP quality improvement project was developed to implement an EBP anxiety
screening and treatment protocol for adults in a primary care clinic to increase early
identification and improve management of GAD.
Plan
The plan cycle requires the development of a purpose statement for the proposed project,
expected outcomes, and steps of execution that include the population and time frame for the
project (AHRQ, 2015). This cycle also requires defining details of the change, the prediction,
and the data to be collected. The plan cycle defines the what, who, when, and where of the
change and data and predicts the outcome (IHI, 2019).
Applicable to this EBP project, during the plan cycle, observations for a quality
improvement change for GAD screening and treatment in a primary care clinic were made,
followed by the development of a purpose statement. The predicted outcome was that
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implementation of a quantifiable anxiety screening tool would increase early identification and
improve management of adults with GAD was established.
Do
Once all the planning for the project is complete, the plan cycle is complete, and the do
cycle begins. The do cycle occurs when the change is implemented and detailed observations
about the process are made (AHRQ, 2015). The do cycle refers to the implementation phase of a
project (IHI, 2019). The do describes what was studied, what occurred, observations, and
problems noted.
In the context of this EBP project, the do cycle was defined as the implementation of a
protocol for a quantifiable anxiety screening method and EBP anxiety treatment for GAD in an
adult primary care practice followed by a retrospective and prospective review of the electronic
health records (EHRs)/charts.
Study
Once the organizational change has been implemented and data has been collected, the
study cycle begins. The study cycle requires an analysis of the results. The data is analyzed, and
then actual outcome(s) are compared to the predicted outcome(s). This is also the time data is
analyzed to see if benchmarks that were set have been met. During the study cycle, the project
team reports the findings to stakeholders, determines the results, and uses the results to identify
what, if any, additional changes are necessary (AHRQ, 2015).
In the context of the implementation of an EBP anxiety screening and treatment protocol,
the study cycle was defined as the period of time for analysis and learning about the processes
that occurred during the implementation phase of the EBP anxiety screening and treatment
protocol.
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Act
After studying the effects of the practice change, warranted changes to be made for a
future PDSA cycle are noted, if found (IHI, 2019). During the act cycle, changes needed to be
made for sustainability are reported (IHI, 2019). In the context of the implementation of an EBP
anxiety screening and treatment protocol, the act cycle involved reporting the findings to the
stakeholders and making necessary recommendations to the protocol process or to existing
treatments previously described.
Objectives
The purpose of this quality improvement project was to implement an EBP anxiety
screening and treatment protocol for adults in a primary care clinic to increase early
identification and improve management of GAD. Therefore, this project had the following
objectives:
1. Train five medical assistants on the administration of the GAD-7 assessment tool
2. Implement an EBP Anxiety screening and treatment protocol
3. Conduct retrospective and prospective chart reviews
4. Evaluate the anxiety screening and treatment protocol implementation process and
GAD identification and management outcomes
In the context of this EBP project in an adult primary care clinic, implementation meant
the practice change occurs by asking every patient, at every health visit, if they had felt anxious,
worried or fearful, more times than not, in the last 6 months, as the Diagnostic and Statistical
Manual 5th edition (DSM-V) diagnostic criteria recommends. Patients who answered “yes” and
who agreed were screened with the GAD-7 screening tool; a score is tallied, the primary care
provider interprets the score to an anxiety level and then uses the anxiety level to assist in
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prescribing EBP treatment, such as lifestyle modifications, SSRIs, SNRIs, mental health
referrals, psychotherapy, or combination therapy. In the context of this EBP project, improved
management meant the primary care provider prescribed treatment based on the GAD-7 anxiety
level according to an EBP protocol.
Significance of Evidence-Based Practice Project
Healthcare Practice
An anxiety assessment tool serves to enhance the provider’s assessment, diagnostic, and
treatment skills for recognizing GAD, rating its severity, and identifying the need for
implementing EBP treatment (Jordan et al., 2017). The routine use of an anxiety screening tool
can accurately identify GAD in a timely manner. Implementation of the GAD-7 anxiety
screening tool enhances the primary care provider’s awareness and understanding of the
significance of an anxiety level. A calculated anxiety level can establish a foundation for the
provider to implement initial GAD treatment (Abberger et al., 2017). Identifying a patient’s
anxiety level guides the provider in selecting a corresponding level of appropriate EBP GAD
treatment such as education and lifestyle modifications, CBT, SSRI, and/or SNRI therapy, and/or
mental health provider referral (Locke et al., 2015; NICE, 2011; Waters et al., 2015).
Healthcare Outcomes
Primary care providers who incorporate routine use of an anxiety screening tool and
implement an EBP treatment protocol enhance the quality of life for adults with GAD. An
anxiety assessment tool that illuminates anxiety severity assists the provider and the individual
with acknowledging the severity of GAD and guiding the selection of appropriate evidencebased treatment. Increasing the quality of life for adults with GAD is achievable by prescribing
appropriate EBP treatment that decreases anxiety exacerbations and reduces symptom severity
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(Waters et al., 2015). CBT and/or SSRIs or SNRIs, implemented by a primary care provider for
GAD treatment, can effectively control GAD symptoms and enhance the lives of individuals
with GAD (Locke et al., 2015).
Healthcare Delivery
A study by Jordan et al. (2017) demonstrated that the implementation of an anxiety
assessment tool in primary care settings enhances delivery of healthcare, contributes to decreased
healthcare costs secondary to accurate and timely diagnosis, and assists clinicians with managing
the complexity of GAD symptoms. Timely and appropriate identification and treatment of
anxiety in the primary care setting may contribute to collaboration among members of the
healthcare team (Jordan et al., 2017). As a result of decreased costs, increased management
skills, and collaboration, healthcare delivery for adults with GAD can be more straightforward
and effective (Jordan et al., 2017).
The Affordable Care Act (ACA) and the Medicare Access and Children’s Health
Insurance Program (CHIP) Reauthorization Act (MACRA) describes value-based purchasing
(VBP) as a healthcare delivery reimbursement system that designates pay for services based on
the quality and cost-effectiveness of healthcare services rendered (Chee, Ryan, Wasfy, &
Borden, 2017). EBP is the standard to which providers should practice healthcare delivery; EBP
is examined for safety and effectiveness (Melnyk & Overholt, 2015).
Healthcare Policy
GAD can cause vulnerability for sufferers; therefore, advocating for the well-being of
these individuals with a timely diagnosis and appropriate EBP treatment in primary care is
pertinent. This EBP quality improvement project advocates for the routine use of an anxiety
screening tool in the primary care setting. Additionally, this EBP quality improvement project
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advocates for compliance with implementation of appropriate EBP GAD treatments based on the
scored anxiety severity.
This EBP project should be adopted as a standard of care. All patients, at every visit,
should be asked the basic questions of GAD diagnostic criteria. Every patient who confirms they
have experienced GAD symptoms for 6 months, as the DSM-V diagnostic criteria recommends,
should be provided the GAD-7 screening tool to quantify an anxiety level (Locke et al., 2015).
The primary care provider should interpret the anxiety level and select a corresponding EBP
recommendation for treatment.
This EBP project can also provide a standard of care for prescribing benzodiazepines for
GAD. Benzodiazepines should only be used short term for severe anxiety, if necessary, to
augment treatment. Benzodiazepines should only be used long-term, on a strict as needed basis,
if the provider has established that the patient experiences panic attacks (Locke et al., 2015;
NICE, 2011). If a patient experiences panic attacks, the provider should consider quantifying the
monthly number of panic episodes and only prescribe low-dose benzodiazepines for the exact
number of episodes expected monthly, and as-needed follow-up should ensue.
Summary
GAD is a prevalent, chronic condition that disrupts the quality of life in sufferers.
Individuals with GAD often present to primary care providers with symptoms of GAD;
therefore, a prompt diagnosis and implementation of an EBP treatment plan is necessary.
Currently, anxiety screening and evidence-based practice treatment for adults in primary care are
suboptimal. Benzodiazepines are often prescribed for GAD and misused, which can lead to
increased morbidity and/or mortality rates. Prompt screening for GAD with the GAD-7
screening tool is proven to be accurate and efficient in the primary care setting. Effective EBP
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GAD treatment is achievable with lifestyle modifications, relaxation techniques, SSRIs, SNRIs,
psychotherapy, and/or mental health referrals. A quality improvement EBP project was
developed using the PDSA theory for the implementation of the GAD-7 screening tool and an
evidence-based treatment protocol in adults with GAD in the primary care setting.

16
Chapter Two: Review of the Literature
Performing a systematic review of the literature is an essential component of planning
evidence-based practice (EBP) projects. An EBP project is conducted based on existing
evidence acquired thorough a review of the literature (Polit & Beck, 2017). This review requires
an evaluation and critique of the literature and the dissemination of the literature review’s
findings into practice for improved patient outcomes (Polit & Beck, 2017). An in-depth
literature review was conducted for the purpose of demonstrating the gap in care for individuals
with generalized anxiety disorder (GAD) and to find evidence of effective anxiety screening and
treatment interventions. This chapter will review the search strategies used for the literature
review and discuss the evidence found to support an EBP intervention for screening and treating
individuals with GAD in a primary care practice in South Florida.
Search Strategies
A comprehensive review of the literature was conducted using the following search
engines: Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane,
EBSCO Complete, Health and Medical Collection database, Google Scholar, PubMed,
PsycINFO, and Up-to-Date. Most of the retrieved articles were published between 2013-2018.
Exceptions to the 5-year timeframe were seminal works on the generalized anxiety disorder 7item (GAD-7) screening tool by Spitzer, Kroenke, Williams, and Lowe (2006) and the GAD
clinical practice guidelines by National Institute for Health and Care Excellence [NICE] (2011).
The key words used for searching were anxiety, assessment, treatment, management,
generalized, and guidelines. The key terms used were: clinical practice guidelines for anxiety
screening, clinical practice guidelines for anxiety treatment, evidence-based practice for
generalized anxiety disorder screening, evidence-based practice for anxiety treatment,
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generalized anxiety disorder, anxiety management in primary care, anxiety screening in primary
care, benzodiazepine misuse in primary care, and mental health professionals. The search
yielded 57 articles, and of those articles, 17 were included in this literature review. The other 40
articles were excluded because they were older than 5 years, did not examine nonspecific anxiety
or GAD, did not include a primary care population or setting, or included children in the studies.
The search revealed 17 articles that met the inclusion criteria of within 5 years old, included
either nonspecific anxiety or GAD, were pertinent to the primary care setting, researched anxiety
prevalence in primary care, and/or inadequate anxiety screening, inadequate EBP anxiety
treatment, clinical practice guidelines or recommendations, anxiety screening tools, and/or EBP
GAD treatment for adults, and included an adult-only population.
Retrieved information from professional and governmental organizations on the topic of
anxiety was also necessary to identify any existing recommendations and/or clinical practice
guidelines for anxiety screening and treatment. The websites viewed for professional and
governmental organizations were American Academy of Family Physicians (AAFP), American
Psychiatric Association (APA), Anxiety and Depression Association of America (ADAA),
Community Care of North Carolina, National Institute for Health and Care Excellence (NICE),
National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National
Alliance on Mental Illness (NAMI), U.S. Department of Veteran’s Affairs (VA), and the World
Health Organization (WHO) .
Literature Reviewed
A review of the literature elucidated that there is a lack of consistent and uniform use of
screening methods to quantify GAD anxiety levels and a lack of EBP treatment being prescribed
by primary care providers for adults with GAD (Goldberg et al., 2016; Olarui et al., 2015;
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Roberge et al., 2015; Weisberg et al., 2014; Wiegner et al., 2015). The literature also made clear
that adults with GAD often presented to their primary care provider with anxiety symptoms,
despite the reason for their healthcare appointment (Goldberg et al., 2016; Olarui et al., 2015;
Roberge et al., 2015; Weisberg et al., 2014; Wiegner et al., 2015). Despite the lack of uniform,
quantifiable screening and best practice treatment being prescribed for GAD, the primary care
provider can capture patient diagnosis of GAD and implement appropriate treatment. The
literature reveals that screening for GAD with a quantifiable tool, such as the GAD-7 screening
tool, and corresponding EBP treatment, such as selective serotonin reuptake inhibitors (SSRIs),
selective norepinephrine reuptake inhibitors (SNRIs), mental health referrals, and psychotherapy
are best practices for screening and treating adults with GAD in primary care (Jordan et al.,
2017; Locke et al., 2015; Spitzer et al., 2006).
The literature review included a large criterion-standard study, which is a study that
examines new tests, protocols, and results that examined the reliability of the GAD-7 screening
tool (Spitzer et al., 2006). Additionally, two large systematic reviews were included in the
literature that examined the efficacy of psychotherapy treatment for GAD (Bandelow et al.,
2015; Marin, Campayo, Montoyo, Olmo, & Cuijpers, 2018). Two large meta-analyses were
performed to investigate the effectiveness of selective serotonin reuptake inhibitors (SSRIs),
SNRIs, and benzodiazepines for GAD treatment (Bandelow et al., 2015; Slee et al., 2019). One
randomized controlled trial (RCT) was conducted to compare the efficacy of psychotherapy,
SSRIs, SNRIs, and benzodiazepines for GAD treatment (Wetherell et al., 2013). The review of
literature revealed clinical practice guidelines that recommended the implementation of a
quantifiable anxiety screening tool and using an anxiety level to select EBP treatment for adults
with GAD in primary care (ADAA, 2015; Locke et al., 2015; NICE, 2011).
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Anxiety Prevalence in the United States
Several professional and governmental organizations have released data disclosing the
prevalence of anxiety among adults living in the United States (U.S). Every year, about 40
million adults, ages 18 and older, experience an anxiety disorder (ADAA, n.d.). The ADAA
(n.d.), the NAMI (2019), and the NIMH (2017a) present anxiety prevalence statistics from the
National Comorbidity Study Replication (NCS-R), which was performed by a telephone survey
of adults living in the U.S. who were asked specific questions relating to anxiety diagnostic
criteria. The NCS-R found that 18.1% of adults living in the U.S. have an anxiety disorder
(ADAA, n.d.; NAMI, 2019; NIMH, 2017a). The NCS-R found that GAD is responsible for
2.7% of all anxiety disorders in adults living in the U.S. (NIMH, 2017b).
Anxiety in Primary Care
A quantitative field study of 587 patients, led by the WHO, was conducted by Goldberg
et al. (2016). The aim of the study was to examine the Primary Health Care Version of ICD-11’s
descriptions for Bodily Stress Syndrome (BSS) and Health Anxiety (HA) to investigate whether
those descriptions correlate to primary care provider’s observations of BSS and HA and how
BSS and HA relate to other depressive and anxiety-related disorders. Participants were given the
Clinical Interview Schedule-Revised (CIS-R), which is a diagnostic tool used by trained
personnel to detect common mental health disorders, such as anxiety. The study concluded that
78.9% (n = 587) of patients had an associated anxiety or mood disorder when presenting to their
primary care provider. This study demonstrated that anxiety disorders are common in the
primary care setting and individuals presented to their primary care provider with anxiety,
despite the reason for their appointment.
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An observational study of 587 primary care patients, among five primary care clinics,
was conducted by Wiegner et al. (2015) to investigate prevalence of stress in working adults who
were seeking primary care services, despite the reason for the healthcare visit. Participants were
provided a questionnaire that quantified stress levels by asking questions about how often the
participant experienced stress. For participants with a high stress level, determined by the
questionnaire, a separate questionnaire that determined exhaustion/burnout and another
questionnaire that determined anxiety and depression were provided to the participants. As a
result of a stress level that was higher than a little bit of stress, 59% of the 587 participants had a
stress level that qualified them to complete anxiety screening via the self-reporting Hospital
Anxiety and Depression Scale (HAD), which quantified an anxiety level. The anxiety screening
revealed 64% of the 305 participants presenting to their primary care provider had symptoms of
anxiety. This study showed that individuals who go to their primary care provider, despite their
primary complaint, may have anxiety that can be detected at that appointment.
A cohort study surveying 373 patients meeting GAD diagnostic criteria was conducted by
Roberge et al. (2015). The purpose of the study was to examine the use of mental health services
by primary care patients with GAD, determine the detection rate of GAD in primary care, and
examine correlates of treatment to clinical practice guidelines. The participants were surveyed in
waiting rooms of 67 primary care offices and by telephone and web using a two-part interview.
The first part of the study interview included a structured interview, the Composite International
Diagnostic Interview-Simplified (CIDIS), to determine if the participant met diagnostic GAD
criteria. If so, the second part of the interview included a series of questions regarding the
participant’s GAD diagnosis including: the type of clinical provider who was sought for consult
regarding mental health concerns, the type of provider who diagnosed their GAD, medication
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use, and psychotherapy and mental health services. Roberge et al. (2015) discovered that 87.4%
of the 373 participants with mental health concerns had consulted a primary care provider in the
previous 12 months. Of the 373 participants seeking consultation for mental health concerns,
52.5% had been diagnosed with GAD by a healthcare professional in the previous 12 months.
Roberge et al. (2015) concluded that 32.6% of the 373 participants received adequate treatment,
such as mental health services and/or medication aligned with clinical practice guidelines.
Roberge et al. (2015) provided pertinent data that demonstrated individuals with GAD
predominately sought out primary healthcare services for their symptoms; however, GAD was
not recognized by primary care providers in nearly half of individuals with GAD, and EBP
treatment was inadequate.
Inadequate GAD Screening and Treatment
An Olarui et al. (2015) meta-analysis of 24 studies, with a combined total of 34,902
patients, examined anxiety diagnosis in primary care. The study investigated unassisted
(professional diagnostic interviewing with no use of an anxiety screening tool) and assisted (use
of any anxiety screening tool that rates anxiety severity) anxiety diagnoses by primary care
providers to determine if assistive screening was more valuable for the detection of anxiety than
clinical judgment (unassisted screening) by primary care providers. The results of the study
showed primary care providers who did not utilize an anxiety screening tool (unassisted)
demonstrated a 30.5% sensitivity and 91.2% specificity for classifying anxiety disorders, and
primary care providers who used an anxiety screening tool (assisted) were more accurate in
identifying anxiety disorders, with a 63.6% sensitivity and 87.9% specificity for diagnosing
anxiety. This large sample size study demonstrated there was no uniform and consistent
approach to screening for anxiety in primary care because some providers used professional
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diagnostic interviewing, and some used an anxiety screening tool. The study revealed utilizing
an anxiety screening tool enhanced the accuracy of diagnosing anxiety in primary care.
Weisberg et al. (2014) conducted an observational longitudinal study of 534 adult
patients among 15 primary care settings to investigate the adequacy of anxiety treatment in the
primary care setting. All participants (n = 534) met anxiety disorder order criteria, which was
assessed using a 32-item anxiety self-report survey and a Structured Clinical Interview for
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), which was
followed by an interview about their anxiety treatment plans at the intake of the study (first
appointment) and during follow-up appointments at 6 months, 12 months, and then once a year
for a total 5 years. Over a 5-year period, data gathered from the interviews was utilized to
examine the adequacy of psychotherapy and/or pharmacological treatment provided by primary
care providers for participants with anxiety. At the first appointment of the study, findings
showed that 19% of participants were being prescribed adequate pharmacological treatment;
14% were referred for cognitive behavioral therapy (CBT), which is a form of psychotherapy;
and 5% of participants received a combination of pharmacological and CBT treatment.
Adequate pharmacotherapy was defined as a SSRI, SNRI, or benzodiazepine medication(s)
approved for anxiety treatment and given at the recommended dose and timeframe for treating
anxiety. Adequate CBT was defined as achieving an adaptive behavior to resolve the anxiety
and restructuring thinking during anxiety. At the conclusion of the 5-year study, 60% of
participants were being prescribed adequate pharmacological treatment, 36% psychotherapy, and
26% combination therapy.
Bachhuber, Hennessy, Cunningham, and Starrels (2016) conducted a quantitative study
to examine benzodiazepine prescribing trends and mortality related to benzodiazepine overdose
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in adults living in the U. S. Bachhuber et al. (2016) retrieved data about filled benzodiazepine
prescriptions from the Medical Expenditure Panel Survey (MEPS) for the years 1996-2013. The
MEPS is conducted by the U.S. Department of Health and Human Services: Agency for
Healthcare Research and Quality (AHRQ), which collects and reports data about the use, cost,
and health insurance of medical services in the U.S. (AHRQ, 2016). From this data, Bachhuber
et al. (2016) analyzed the number of adults who filled prescriptions for benzodiazepines and the
quantity of prescription benzodiazepines that were filled each year. Benzodiazepine overdose
related mortality, for the years 1999-2013, was also examined by retrieving data from the
Centers for Disease Control and Prevention (CDC). The study illuminated that the number of
U.S. adults who filled a prescription for benzodiazepines increased 67% between 1996 and 2013,
from 8.1 million to 13.5 million prescriptions. The quantity of filled benzodiazepine
prescriptions was the equivalent to 1.1 kilograms (kg) in 1996, which tripled to 3.6kg of
benzodiazepines per 100,000 adults filled in 2013. Benzodiazepine overdose deaths quadrupled
from 0.58 to 3.07 per 100,000 adults over that same period of time. The study revealed 56.1% of
benzodiazepines were prescribed for anxiety treatment.
A cross-sectional study of 368,891 veterans was conducted by Carico et al. (2018) to
investigate the amount of overlap of benzodiazepine and opioid prescriptions were ordered for
U.S. veterans with Medicare Part D and Veterans Affairs (VA) prescription benefits. The study
reported 31.4% of veterans (n = 368,891) had overlapping usage of benzodiazepine and opioid
medications. Of the veterans taking overlapping benzodiazepines and opioids, 17.3% of those
veterans used VA benefits only, 16.5% used Medicare benefits only, and 23.1% used both VA
and Medicare benefits. Overlap use of high dose benzodiazepine and opioid medications lasted
at least 30 days in 2.3% of VA prescription benefit only users, 2.9% Medicare Part D only users,
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and 4.7% of dual users (Medicare Part D and VA prescription benefits). The study concluded by
stating that veterans with dual Medicare and VA prescription benefits were at an increased risk
of receiving overlapping opioid and benzodiazepine prescriptions, which can be potentially
dangerous. This large sample size study illuminated the prevalence of benzodiazepines used in
combination with opioids, which places individuals at risk for dangerous complications. This
research helps demonstrate that unnecessary, increased prescribing of benzodiazepines can occur
concurrently with other dangerous and addictive medications.
Clinical Practice Guidelines for Anxiety Screening and Treatment
The Institute of Medicine (IOM) Roundtable on Evidence-Based Medicine developed a
goal to ensure that accurate, timely, and current best evidence is implemented in 90% of clinical
decision making by the year 2020 (Olsen, Aisner, & McGinnis, 2007). Clinical practice
guidelines and recommendations are based on best evidence that has been examined for
effectiveness and optimal patient outcomes (Melnyk & Fineout-Overholt, 2015). The ADAA
(2015), Locke et al. (2015), and NICE (2011) have developed and published recommendations
for GAD management. The ADAA (2015), Locke et al. (2015), and NICE (2011) all
recommend determining an anxiety severity or impairment level that can be utilized to select, in
collaboration with the patient, appropriate treatment such as psychotherapy, SSRIs, SNRIs,
mental health referral, or combination treatment for adults with GAD in primary care.
The Generalized Anxiety Disorder in Adults: The NICE Guideline on Management in
Primary, Secondary and Community Care, National Clinical Guideline [CG113] was developed
by the National Collaborating Centre for Mental Health and commissioned by NICE. The NICE
(2011) clinical practice guidelines provide a stepwise approach that guides the primary care
provider through EBP diagnostic and treatment recommendations for adults with GAD. NICE
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(2011) recommends prompt diagnosis of anxiety, the establishment of level of anxiety severity
and functional impairment, and ruling out any pathological conditions. NICE (2011) presents
the GAD management clinical practice guideline’s protocol as a series of four steps. According
to NICE (2011), selecting treatment for GAD is based on correlate to an anxiety level.
Treatment includes lifestyle modifications, specific SSRIs, specific SNRIs, mental health
referrals, psychotherapy, or combination treatment. Benzodiazepines may be initiated short term
or prescribed for immediate crisis management if an individual is at risk of self-harm. All steps
of treatment should be individualized and selected by considering patient history and risks and
benefits of treatment.
In Diagnostics and Management of Generalized Anxiety Disorder and Panic Disorder in
Adults, Locke et al. (2015) defined the clinical recommendations for diagnosing and treating
adults with GAD. The recommendations are located on the American Association of Family
Physicians’ website. The recommendations include diagnosing anxiety with use of a screening
tool. Locke et al. (2015) suggested the use of the GAD-7 screening tool because of its validity of
sensitivity and specificity. The GAD-7 quantifies an anxiety level. The recommendations
inform that a GAD-7 score of 10 or greater requires anxiety intervention. The following
recommendations for treating GAD are: (a) to rule out potential pathological medical conditions;
(b) provide the individual with education and active listening; (c) implement lifestyle
modifications such as cessation/reduction of nicotine, caffeine, and avoidance of triggers; (d)
prescribe first-line therapy that includes psychotherapy, such as cognitive behavioral therapy
(CBT) alone, or the following SSRIs alone: escitalopram (Lexapro), fluoxetine (Prozac),
paroxetine (Prozac), and sertraline (Zoloft), or the following SNRIs alone: venlafaxine extended
release (Effexor XR), or duloxetine (Cymbalta); or (e) prescribe pharmacotherapy in

26
combination with psychotherapy. The benzodiazepines alprazolam (Xanax), clonazepam
(Klonipin), diazepam (Valium), and lorazepam (Ativan) should only be used short term for
augmentation. A referral to a mental health specialist is warranted for suboptimal/failed
treatment response, atypical presentation, or suspected comorbid psychiatric illness.
Locke et al. (2015) recommend using a GAD screening tool for diagnosing anxiety and
specifically mention the GAD-7. These recommendations underscore the importance of
establishing an anxiety level and correlating the level to EBP treatment selections.
The ADAA published The Clinical Practice Review for GAD (2015) that was developed
by a clinical taskforce that recommends the following first-line treatments for adults with GAD:
psychotherapy, which can consist of cognitive behavioral therapy (CBT), cognitive therapy (CT),
or applied relaxation techniques, or pharmacotherapy, which can consist of the SSRIs,
escitalopram (Lexapro), fluoxetine (Prozac), paroxetine (Prozac), and sertraline (Zoloft), or
SNRIs venlafaxine extended release (Effexor XR), or duloxetine (Cymbalta). These
interventions for GAD were developed by the GAD Clinical Practice Review Task Force that
included Powers, Becker, Gorman, Kissen, and Smits (2015).
Effectiveness of GAD-7 Screening Tool
Spitzer et al. (2006) developed and tested a short, self-reportable GAD screening tool, the
GAD-7 screening tool, designed to assist in diagnosing and quantifying anxiety levels in adults
with GAD in primary care. The validity and reliability of the GAD-7 screening tool was tested
in a criterion-standard study of 2,740 adults in 15 primary care practices. Analysis of the data
revealed the tool was 82% specific and 89% sensitive, with an internal consistency of 0.92 for
diagnosing GAD in adults in the primary care setting.
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Jordan et al. (2017) conducted a study of 3,404 patients among 33 primary care clinics to
examine whether the questions on the GAD-7 screening tool accurately diagnose GAD. Each of
the seven items (questions) were individually weighted to determine their grade of reliability to
diagnose GAD. Jordan et al. (2017) used psychometric analysis to determine the discriminatory
power of each question. The statistical analysis of the seven questions and corresponding scores
revealed an overall reliability of 0.91 of the GAD-7 screening tool. The findings illuminate that
the GAD-7 is an accurate tool for screening adults for GAD in primary care.
Evidence-Based Treatment for GAD
A meta-analysis of 234 studies, which included 37,333 patients, was performed by
Bandelow et al. (2015) to compare psychological, pharmacotherapy, and combined treatment
(psychological and pharmacotherapy) for GAD. Randomized controlled trials (RCTs) that
investigated GAD, psychological therapies, and pharmacotherapy for GAD treatment were
eligible for inclusion in the meta-analysis. An analysis of 234 studies conducted by Bandelow et
al. (2015) discovered that treatment for GAD should include psychotherapy, pharmacotherapy,
or combination therapy, and selection of treatment should incorporate patient preference,
consideration of the side effects of medications, and the cost and/or wait period to start
psychotherapy. Further, all GAD treatments were found equally effective at improving the
quality of life in adults with GAD. The study, which incorporated a large sample size and a
diverse review of studies, enhances confidence that psychotherapy, pharmacotherapy, or
combination therapy are effective GAD treatments.
A meta-analysis of 50 studies that included 2,801 patients by Marin, Campayo, Montoyo,
Olmo, and Cuijpers (2018) compared CBT to relaxation training for anxiety treatment. A
multivariate meta-regression analysis of 50 studies found that relaxation techniques and CBT
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provide equivocal results for treating GAD. This meta-analysis also demonstrated
psychotherapy is an effective treatment for individuals with GAD.
An RCT of 704 adults among 26 primary care providers conducted by Rollman et al.
(2018) examined the outcomes of a collaborative care program that consists of computerized
cognitive behavioral therapy (CCBT) and an internet support group (ISG) for anxiety treatment
compared to a CCBT-only program in adults with anxiety. The study utilized mental health
professionals who telephoned participants to educate them about their randomly assigned
therapy: either the CCBT only or ISG/CCBT programs. The mental health professionals acted as
care managers who would regularly monitor participation trends throughout the 8-week program
and update the primary care providers on the participants’ progress. Participants were
administered the GAD-7 screening tool before intervention began and after completing their
assigned 8-week program. The study concluded that participants assigned to the collaborative
ISG and CCBT group did not have added benefits in comparison to the CCBT group that proved
more effective in participants with anxiety. This study provided evidence that collaboration
between mental health specialists and primary care providers and CBT improve outcomes of
individuals with anxiety.
Slee et al. (2019) conducted a systematic review and meta-analysis of 89 RCTs with a
total of 25,441 patients to examine the efficacy of medications used to treat GAD. The metaanalysis performed by Slee et al. (2019) found SSRIs (duloxetine, venlafaxine, and escitalopram)
effective for treating GAD. The study stated in the implications for practice that duloxetine,
venlafaxine, and escitalopram were more efficacious with good acceptability and were effective
at controlling/improving GAD symptomology when compared to those who received placebos
for GAD treatment.
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Wetherell et al. (2013) conducted an RCT of 73 patients to evaluate the long-term GAD
symptom management of combined CBT and the SSRI escitalopram therapy. Participants (n =
73) were recruited in three outpatient clinics. Participants completed a Hamilton Anxiety Rating
Scale (HAM-A), which measures anxiety and was completed at baseline and every 4 weeks
during augmentative therapy and every 2 weeks during maintenance therapy. Participants also
completed the Penn State Worry Questionnaire, which measures uncontrollable worry, at
baseline and end of the study. The study was divided into three phases: acute, augmentation, and
maintenance. Every participant received escitalopram for 12 weeks in the acute phase. At the
completion of the acute phase, participants completed the HAM-A. Participants with a 20%
improvement in GAD symptoms moved into the augmentation and maintenance phases. The
augmentation and maintenance phases included a random assignment to either: 16 weeks of
escitalopram and 16 sessions of CBT therapy, with 28 weeks of escitalopram for maintenance
therapy; 16 weeks escitalopram only, with 28 weeks of escitalopram for maintenance therapy; 16
weeks of escitalopram and 16 sessions of CBT therapy, with 28 weeks of placebo for
maintenance therapy; or 16 weeks escitalopram only, with 28 weeks of placebo for maintenance
therapy. The study revealed that there was no significant change between the escitalopram-only
group and the escitalopram with combination CBT group for measurements of anxiety when
measured with HAM-A. There was, however, a threefold decrease in a state of worry measured
by the Penn State Worry Questionnaire for participants who received escitalopram and CBT
combined therapy.
Synthesis of Findings
The lack of a consistent and uniform anxiety screening method for GAD in primary care
was evident in the literature review. Four studies demonstrated that individuals with anxiety
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symptoms commonly present to their primary care provider (Goldberg et al., 2016; Roberge et
al., 2015; Weisberg et al., 2014; Wiegner et al., 2015). There was a lack of consistent and
uniform use of quantifiable screening methods for GAD by primary care providers (Goldberg et
al., 2016; Olarui et al., 2015; Roberge et al., 2015; Weisberg et al., 2014; Wiegner et al., 2015).
Further, studies demonstrated primary care providers deliver inadequate EBP treatment for adults
with GAD (Furbish et al., 2017; Weisberg et al., 2014). Two large studies illuminated the
increasing trend of benzodiazepine prescribing and misuse related to anxiety disorder treatment,
which can result in dependency and/or mortality (Bachhuber et al., 2016; Carico et al., 2018).
Despite the inconsistencies of GAD screening methods, the Generalized Anxiety
Disorder 7-item (GAD-7) screening tool renders an anxiety level and has been proven effective
at accurately diagnosing GAD in primary care (Jordan et al., 2017; Locke et al., 2015; Spitzer et
al., 2006). Best practice recommendations for GAD screening and treatment for adults in
primary care have been developed and well-studied. Consistent use of an anxiety screening tool,
such as the GAD-7, has been carefully examined and recommended for primary care provider
use (Jordan et al., 2017; Locke et al., 2015; NICE, 2011; Spitzer et al., 2006). Effective EBP
treatment recommendations for GAD state that a provider should collaborate with the patient to
select an appropriate treatment that correlates to the patient’s anxiety level and preference, such
as lifestyle modifications, SSRIs, SNRIs, mental health referrals, psychotherapy, and/or
combination treatments (Locke et al., 2015; NICE, 2011).
Advantages and Disadvantages
A review of the literature revealed three disadvantages. The first disadvantage was that
not one uniform method for GAD screening in primary care was found in the current literature.
Two types of anxiety screening methods are being utilized: interview and anxiety screening
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tools. Additionally, various types of interview and anxiety screening tools, including those that
are not specific to GAD, are being used in primary care. The second disadvantage was that there
is no evidence that GAD treatment is being prescribed in correlation to a measured anxiety level,
as recommended by clinical practice guidelines. The third disadvantage was a failure to examine
how quantifying a GAD anxiety level can assist primary care providers to prescribe EBP
treatment for adults with GAD.
The literature review also revealed advantages. A review of literature illuminated the
opportunities that primary care providers had to capture a GAD diagnosis and treat GAD in adult
patients seeking primary care services. The literature demonstrated most primary care providers
do not implement best practices for GAD screening and treatment (Bachhuber et al., 2016;
Carico et al., 2018; Goldberg et al., 2016; Olarui et al., 2017; Roberge et al., 2015; Weisberg et
al., 2014; Wiegner et al., 2015). This underscores the need for implementation of a
comprehensive EBP GAD screening and treatment change in primary care for adults with GAD.
Gaps in the Literature
There was a lack of precise reproduction of screening methods and treatment for GAD in
the studies of the literature review. Studies that examined one uniform GAD screening tool that
quantifies an anxiety level to utilize for the implementation of EBP treatment for adults with
GAD would enhance the evidence. A total of four studies utilized an anxiety screening method.
Three studies utilized three different methods of professional interviewing—the CIS-R, CIDIS,
and Structured Clinical Interview for DSM-IV anxiety criteria—and one meta-analysis did not
specify the interviewing technique used for anxiety screening (Goldberg et al., 2016; Olarui et
al., 2017; Roberge et al., 2015; Weisberg et al., 2014). Two studies utilized an anxiety screening
tool, one study implemented HAD, and the other study, a meta-analysis, did not specify the
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anxiety screening tool(s) implemented, and none of the studies used a screening tool specific to
GAD (Olauri et al., 2015; Wiegner et al., 2015). Further, the review of literature illuminated a
lack of EBP treatment prescribed for adults with GAD in primary care. Clinical practice
guidelines recommend correlating anxiety level to EBP treatment for adults with GAD in
primary care (Locke et al., 2015; NICE, 2011). None of the studies investigated whether an
anxiety level was used to assist in prescribing adequate EBP treatment for GAD (Bachhuber et
al., 2016; Carico et al., 2018; Roberge et al., 2015; Weisberg et al., 2014). Recommendations for
future studies included examining a consistent anxiety screening method, investigating the
frequency that primary care providers acquire an anxiety level to use as a foundation for
prescribing EBP treatment, and studying how an anxiety level can assist in prescribing GAD
treatment.
Utilization of Findings for Intervention
Despite a lack of uniform and consistent screening and treatment for adults with GAD in
primary care, several studies demonstrated that anxiety can be promptly diagnosed, and
appropriate management with EBP treatment(s) is achievable in the primary care setting.
Improving the quality of life in adults with GAD requires prompt and effective treatment. The
GAD-7 is a well-studied screening tool with an 82% specificity and 89% sensitivity and is
reliable and valid for screening adults in primary care settings for GAD (Jordan et al., 2017;
Locke et al., 2015; Spitzer et al., 2006). Clinical recommendations for GAD management were
developed by Locke et al. (2015), NICE (2011), and the ADAA (2015), recommending providers
quantify levels of anxiety through screening and implement EBP practices that include lifestyle
modifications, CBT, SSRIs, SNRIs, mental health referrals and/or combination therapies to
ensure optimal patient outcomes and increase quality of life for adults with GAD.
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Summary
Commonly, individuals with GAD present to their primary care provider for treatment.
GAD screening of adults in primary care is inadequate and does not routinely reveal an anxiety
level. There is also an overall lack of routine implementation of EBP treatment for adults with
GAD in primary care, and when provided, treatment is often inadequate. The GAD-7 screening
tool quantifies an anxiety level and is valid and reliable for use by primary care providers for
diagnosing GAD. Clinical recommendations provide algorithms that correspond an anxiety level
to EBP treatment for adults with GAD in primary care. Best practice evidence found prompt
identification of GAD, followed by the implementation of either CBT, SSRIs, SNRIs, a mental
health referral, or combination therapies effectively provide long-term symptom control and
enhance the quality of life of adults with GAD.

34
Chapter Three: Methodology
Symptoms of generalized anxiety disorder (GAD) vary from mild to debilitating and can
adversely affect quality of life. Inappropriate treatment of GAD, including the inappropriate
prescribing of short-acting benzodiazepines for long-term anxiety treatment, can result in poor
symptom control and cause other negative consequences such as medication abuse (Locke, Kirst,
& Shultz, 2015). Healthcare providers who are thorough and consistent with implementation of
anxiety screening and evidence-based treatment can efficiently and appropriately manage an
individual’s anxiety symptoms and improve his or her quality of life (Locke et al., 2015;
National Institute for Health and Care Excellence [NICE], 2011). This evidence-based practice
(EBP) project implemented a systematic change at a primary care clinic in south Florida that
included screening patients for anxiety with an evidence-based tool that diagnoses and quantifies
a GAD severity level and prescribing GAD treatment according to an EBP protocol. This
chapter will discuss the methodologies used for this Doctor of Nursing Practice (DNP) evidencebased practice (EBP) project for implementing a screening and treatment protocol for GAD in an
adult primary care practice.
Purpose of the Project
The purpose of this quality improvement project was to implement an EBP anxiety
screening and treatment protocol for adults in a primary care clinic to increase early
identification and improve management of GAD.
Project Management
Organizational Readiness for Change
The primary care provider, at the project’s implementation site, expressed a desire and
willingness to change previous practices for anxiety screening and treatment in this primary care
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setting. There was a lack of routine anxiety screening performed for individuals who
complained of anxiety symptoms and no utilization of an anxiety screening tool at this site. The
primary care provider also wanted to reduce the number of benzodiazepines prescribed for
individuals with GAD in this practice.
Risk Management Assessment: SWOT Analysis
During a 5-month observational period, the following strengths, weaknesses,
opportunities, and threats were observed in this primary care practice. The strengths of this
primary care clinical practice included the clinical staff: follows through with tasks, has excellent
rapport with patients and with each other, is receptive to change, and has a culture of positive
teamwork and genuine commitment to deliver high-quality healthcare. The weaknesses of this
practice included: no uniform policy for screening for anxiety existed, a lack of routine screening
for anxiety, anxiety severity screening, utilization of evidence-based anxiety screening tools, and
providers’ inconsistent prescription of EBP treatment(s) that correspond to anxiety severity. The
opportunities for this practice included: the primary care provider’s genuine sincerity to deliver
the best practices available to improve her patients’ outcomes, a request for an anxiety screening
protocol, and her readiness to implement an EBP anxiety screening tool and EBP treatment by
corresponding anxiety treatment to anxiety severity, per a treatment protocol, and the availability
of a valid and reliable tool and treatment algorithm. The threats for the practice included a
potential for attrition in clinical staff, high daily patient volume, and a busy practice that caused
time constraints.
Project Budget
Resources such as people, time, and technology were needed to implement this EBP
project. The protocol training session for the four medical assistants (MAs) included a catered
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lunch. The catered lunch was provided for all 12 employees at the primary care clinic. A 6month subscription for IBM SPSS Software was purchased for data analysis. One package of 12
retractable gel pens in black ink was purchased to provide writing utensils for completing the
Generalized Anxiety Disorder 7-item (GAD-7) screening tool. One 1000-sheet package of copy
paper was purchased for printing the GAD-7 screening tools. One HP Officejet Pro printer ink
cartridge was purchased to print the GAD-7 screening tools. Costs for travel to/from the facility
to implement the project were also calculated according to the 2018 Internal Revenue Service
(IRS) mileage reimbursement rate (See Table 1).
Table 1
Project Budget
Item
Catered lunches for protocol training ($7.24 x 12 people)

Cost
$86.88

IBM SPSS Software (e.g. 6-month subscription x2)

$178.00

Retractable Gel Pens (1 package of 12 pens)

$16.59

Copy Paper (1000 sheets x $0.0339 per sheet)

$33.98

Printer Ink Cartridges (1)

$119.99

Travel to/from facility 92 days (5,016 miles x $0.58 per mile)

$2,909.28

Total Costs

$3,344.72
Design of Intervention

This EBP anxiety screening and treatment protocol, which was a systematic change that
included a retrospective/prospective chart review, was approved by Nova Southeastern
University’s Institutional Review Board (see Appendix A) and the primary care clinical practice
site (see Appendix B). The implementation of the EBP project included the following steps:
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Phase 1
Provide MA training on anxiety screening protocol: Prior to the training, MAs were
explained the purpose of the quality improvement EBP project. Four MAs were trained on the
anxiety screening and treatment protocol that was adopted as standard practice in the clinic via
an interactive PowerPoint presentation, with opportunities provided for questions and answers.
Training included background and significance of anxiety and underscored the importance of
screening patients for anxiety. The training also trained the four MAs on their role in the
screening and treatment protocol. MAs were provided samples of completed GAD-7 tools and
calculated the numerical responses to demonstrate to the project implementer the ability to
accurately calculate (not interpret) the GAD-7 score (see Appendix C). The interactive
discussion of questions and answers demonstrated the MA’s understanding of the training. This
20-minute presentation was provided four times over 1 week to capture and train all four MAs.
Phase 2
Implementation of the EBP anxiety screening and treatment protocol (see Appendix D)
included the following steps for the MAs, primary care providers (PCPs), and the adult primary
care clinic patients.
Step 1. On intake, in addition to routine intake data collection such as vital signs and
changes in medical history, the MA asked all adult patients (at least 18 years of age) the
following question: “Have you experienced feelings of worry, fear, or mental unease over the
past 6 months?” and then documented the patients’ answer of “yes” or “no” in the patients’
electronic health records (EHR; approximately 30 seconds). The Diagnostic and Statistical
Manual of Mental Disorders, 5th edition (DSM-5) informs that anxiety is defined as feelings of
inappropriate worry or fear as, more days than not for 6 months (APA, 2013.
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Step 2. If the patient answered “yes” to the question “Have you experienced feelings of
worry, fear, or mental unease over the past six months?” the MA asked the patient “Are you
having thoughts of killing yourself right now?” If the patient responded “yes,” which indicates
an imminent risk for suicide, the patient was not to be left alone and an immediate mental health
evaluation was to be made (NAMI, 2019). If the patient answered “no,” the MA asked the
patient to complete the self-reportable GAD-7 tool and provided instructions for completing the
questionnaire. Per the practice systems change guideline, all patients were informed that they
had the right to refuse to complete the questionnaire.
For reference, the following governmental and professional organizations provide open access
to the GAD-7: The U.S. Department of Veteran’s Affairs, the National Institute for Mental
Health (NIMH), Substance Abuse and Mental Health Services Administration (SAMSHA),
Patient-Centered Primary Care Collaborative (PCPCC), Community Care of North Carolina,
and the Health Information Library.
Step 3. If the patient agreed to and completed the GAD-7, once completed, the MA took
the GAD-7 from the patient, tallied the score, recorded the score in the patients’ EHR, and
placed the GAD-7 on the chart for the primary care provider to review. This step took
approximately 3 minutes.
Step 4. Prior to seeing the patient, the PCP reviewed the patients’ answers on the GAD7, validated the MA’s scoring of the GAD-7, and reviewed and interpreted/quantified the
patients’ anxiety level according to the GAD-7 instructions, which includes level of anxiety
cutoff points of none to minimal (0-4 points), mild (5-9 points), moderate (10-14 points), and
severe (15 or more points) anxiety. This step took approximately 3 minutes.
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Step 5. The PCP discussed the GAD-7 anxiety score with all patients who completed a
GAD-7 and assessed the patient for any underlying medical conditions that present with the same
symptoms of anxiety by performing a full physical assessment and review of systems for any
patient who scored greater than four on the GAD-7. This step’s time varied between 5 and 15
minutes.
Step 6. The PCP discussed with the patient what his or her anxiety score meant (level =
minimal, mild, moderate, or severe) and discussed the following anxiety management based on
what the patient scored. This step’s time varied between 5 and 15 minutes.
An anxiety level of 0-4 (minimal) required a follow-up at the patient’s next regularly
scheduled visit. For an anxiety level of 5-9 (mild), the PCP: (a) educated the patient about
anxiety, (b) actively listened to the patient’s concerns and requests for treatment, (c) considered
the patient’s request for treatment, (d) recommended lifestyle modifications, and (e) educated
patients on what lifestyle modifications should be made to improve symptomology, including
different relaxation techniques. For an anxiety level of 10-15 (moderate), the PCP: (a) provided
all the recommendations for a mild anxiety level and (b) considered the patient’s clinical history,
current medications, allergies, and patient preferences before selecting an anxiety treatment that
included any of the following EBP treatments (and provided patient education on all options,
risks/benefits ratios, and expected outcomes of each option): cognitive behavioral therapy
(CBT), a selective serotonin re-uptake inhibitor (SSRI), a selective norepinephrine re-uptake
inhibitor (SNRI), or a combination of CBT and either a SSRI or SNRI, and follow-up in 6 weeks.
For an anxiety level of 15 or greater (severe), the PCP: (a) provided all the recommendations for
a mild anxiety level, (b) provided referral and contact information for a mental health specialist,
(c) facilitated scheduling with a mental health provider appointment if possible, (d) followed up
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in 6 weeks and PRN, (e) ensured a 6-week follow-up appointment was scheduled, and (f)
educated the patient to call the PCP immediately and make an appointment if symptom severity
or frequency increased (see Appendix D).
This EBP protocol for anxiety treatment was adapted/modified from Community Care of
North Carolina (2018), and anxiety screening and treatment clinical recommendations by Locke
et al. (2015), and National Institute for Health and Care Excellence (NICE, 2011; see Appendix
E).
Step 7. The PCP documented GAD-7 scores and interpretation and anxiety management
plans were collaboratively decided upon with patients.
Phase 3
A retrospective chart review for 2 months of data prior to the implementation of the
anxiety screening and treatment protocol implementation was conducted. The retrospective chart
review occurred over 4 weeks.
Phase 4
A prospective chart review for 2 months of data after the implementation of the EBP
anxiety screening and treatment protocol was conducted. The prospective chart review occurred
over 4 weeks.
Setting
The setting for this EBP project was located in an adult primary care practice in
Southeastern Florida.
Sample
A combined 673 adult, primary care electronic health records (EHRs)/charts (N = 673)
were reviewed. The pre-implementation retrospective and post-implementation prospective
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chart reviews revealed 178 charts (n = 178) included a documented active diagnosis and
treatment for anxiety on the date of service for the time which the chart was reviewed. Of those
178 charts that had an active anxiety diagnosis and treatment plan on the date of service, 81 were
retrospective charts and 97 were post-implementation prospective charts.
Inclusion Criteria
Retrospective chart reviews included all primary care patient charts from March 1, 2019April 30, 2019. The prospective chart review included all primary care patient charts from June
1, 2019-July 31, 2019. Of the 673 charts, 178 were included in the retrospective/prospective
chart review for analysis because they included a documented active diagnosis and management
for anxiety on the date of service for the time which the chart was reviewed. All primary care
patients in this clinic were at least 18 years of age.
Exclusion Criteria
All primary care charts were reviewed; however, charts that did include a documented
active diagnosis and management plan for anxiety were excluded from further analysis.
Recruitment Procedure
This EBP quality improvement project involved retrospective and prospective chart
reviews where no personal identifiable patient data was collected, so there was no recruitment of
participants.
Determination of Sample Size
The implementation phase of this DNP EBP project was 2 months long. Therefore,
prospective chart reviews included the 2 months of charts following the implementation of the
protocol. To allow for a similar amount of charts to be reviewed in the retrospective chart
review, the 2 months prior to the protocol implementation were chosen for chart reviews.
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Data Collection Procedures
Instrumentation
The GAD-7 anxiety screening tool consists of seven (4-point Likert scale type) questions
and is a free public domain tool that takes approximately 2 to 5 minutes to complete (Jordan et
al., 2017; Locke et al., 2015; Spitzer et al., 2006; see Appendix C). Questions consist of asking
the patient to self-report on: feeling nervous, anxious, on edge; not being able to stop or control
worrying; worrying too much about different things; having trouble relaxing; being so restless
that it is hard to sit still; becoming easily annoyed or irritable; and feeling afraid as if something
awful might happen, over the past 2 weeks. One additional question asks the patient if they
checked off any of the previous seven “problems.” If they had, they are asked to answer how
difficult these “problems” listed in the seven questions have impacted their work and/or home
life by checking one of the following responses: not difficult at all, somewhat difficult, very
difficult, or extremely difficult (see Appendix C). Scoring ranges from 0-21, with answer
choices of: not at all sure (0 points), several days (1 point), over half of the days (2 points), and
nearly every day (3 points). The GAD-7 scoring cutoff point for mild anxiety is set at 5,
moderate at 10, and severe anxiety at 15 (Jordan et al., 2017; Locke et al., 2015; Spitzer et al.,
2006).
Validity and Reliability
The GAD-7 screening tool was studied over an 8-month period among 15 primary care
practices and included 2,740 adult participants. Analysis of the data revealed the tool was 82%
specific and 89% sensitive (Spitzer et al., 2006). The GAD-7 is valid and reliable (Cronbach’s α
= 0.92) for diagnosing GAD in primary care, is recommended for anxiety screening, and has
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been used extensively in primary care practice (Jordan et al., 2017; Locke et al., 2015; Spitzer et
al., 2006).
Data Management and Storage
All confidential paper data was kept secured at the intervention site in a locked file
cabinet and only the project implementer has access to the well-hidden key. All data will be kept
for 36 months from the end of the project, and then paper data will be shredded by an electronic
paper shredder that shreds into fine pieces.
Data Analysis
Descriptive and inferential statistics were conducted. Descriptive statistics describe data
and synthesize the findings (Polit & Beck, 2017). The following variables were analyzed: age
range and gender; anxiety screening method pre/post-implementation; anxiety score and level;
and prescribed anxiety treatment pre/post-implementation, such as the type of anxiety treatment
selected, specific lifestyle modifications recommended, relaxation techniques utilized, mental
health referrals, CBT referrals, and pharmacological agents ordered (including type and doses of:
SSRIs, SNRIs, and benzodiazepines). The descriptive analysis reported percentages, frequency
distributions, and means. Descriptive statistics calculated the percentages of the gender and agerange variables of the reviewed charts. Percentages of pre/post-implementation utilization of the
two types of anxiety screening methods used (professional interview and GAD-7 screening tool)
were calculated to determine if the implementation of a quantifiable anxiety screening method to
identify GAD had increased after the training. Anxiety level severity was also calculated and
illuminated the mean and percentages of charts with documented minimal, mild, moderate, or
severe anxiety level. Frequency distributions and percentages were calculated for the: preimplementation retrospective chart reviews and the post-implementation prospective chart
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reviews to determine if there was a change in anxiety screening method and treatment practices
in this primary care practice; post-implementation charts that implemented the GAD-7 screening
tool and the percentages of charts that had a correlated anxiety level to prescribing EBP
treatment to determine if obtaining an anxiety level assisted the primary care provider in
prescribing EBP treatment. Frequency distributions and percentages of post-implementation
charts that utilized the GAD-7 screening tool and the percentages of charts that had a correlated
anxiety level to prescribed EBP treatment to determine if those charts had received changes to
their pre-existing GAD treatment were also calculated.
Inferential statistics conducted included Pearson’s Coefficient Correlation (Pearson’s r).
Pearson’s r is conducted to analyze correlation between variables (Polit & Beck, 2017).
Inferential statistics, Pearson’s r, were utilized to determine whether documented GAD levels
correlated to prescribed EBP treatments.
Ethical Considerations
Protection of Confidentiality
No personal identifiers were needed. The information collected from this study did not
have any identifiable information associated with electronic health records. The recorded data is
a tally of the variables collected, as previously described.
Benefit-to-Risk Ratio
The benefit that is associated with providing anxiety screening resulting in evidencebased treatment is an enhanced quality of life for adults with GAD (Abberger et al., 2017; Locke
et al., 2015; NICE, 2011; Waters et al., 2015). Implementation of an anxiety screening tool in
the primary care setting contributes to decreased healthcare costs secondary to accurate and
timely diagnosis and an increased quality of life (Jordan et al., 2017).
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The benefits to the clinical staff were a consistent, thorough, and systematic evidencebased protocol to assist in the screening and treatment of adults with GAD. The clinical staff
benefited from maintaining compliance in reducing the misuse of Drug Enforcement Agency
(DEA) scheduled medications such as benzodiazepines. In the state of Florida House Bill 21
(HB 21): Controlled Substances now requires that scheduled drugs, including benzodiazepines,
are checked and documented in the EFORSCE Florida Prescription and Drug Monitoring
Program or risk legal consequence (Scott, 2018). The intent of HB 21 is to monitor the
prescribing practices of DEA scheduled medications, such as benzodiazepines (Scott, 2018).
This EBP project may protect the provider from potential investigations, liability, or legal
consequences induced by improper prescribing of benzodiazepines for GAD.
Further, this EBP project for implementation of an anxiety screening and treatment
protocol benefits patients. Best practices recommend screening adults for GAD, in primary care,
with a screening tool that quantifies anxiety levels and then correlating the anxiety level to
prescribing treatment (Locke et. al., 2015). Implementation of best practices for screening and
treating GAD in primary care was proven to accurately identify GAD in adults, decrease
symptoms, and enhance the quality of life in adults with GAD (Locke et al., 2015; NICE, 2011).
Additionally, patients may benefit from reduced use of or possible dependency of
benzodiazepines related to inappropriately prescribing these short-acting medications for longterm treatment and symptomology control.
Summary
An anxiety screening and treatment protocol was implemented in an adult primary care
clinic. A retrospective and prospective chart review was performed to obtain the variables: age
range, gender, number of screenings for anxiety performed before the training and after the
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training, anxiety screening method, level of anxiety, and treatment measures such as lifestyle
modifications, relaxation techniques, mental health referral, CBT, SSRIs, SNRIs, and
benzodiazepines. Descriptive and inferential statistics with Pearson’s r analyzed the variables to
synthesize the findings.
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Chapter Four: Results and Discussion
Generalized anxiety disorder (GAD) can have a substantial impact on the physical and
social aspects of an adult’s life, causing a decrease in the quality of their life (Bentley et al.,
2016; Edmund & Sheppard, 2018; Locke, Kirst, & Shultz, 2015; National Institute of Mental
Health [NIMH], 2017a; NIMH, 2018; Stein & Sareen, 2015). Best practices recommend
screening adults for GAD, in primary care, with a screening tool that quantifies anxiety levels
and then correlating the level to prescribing treatment. A primary care practice did not have a
GAD screening tool and treatment protocol to routinely screen and treat patients with GAD
according to best practices.
Anxiety treatment interventions such as specific selective serotonin re-uptake inhibitors
(SSRIs), specific selective norepinephrine re-uptake inhibitors (SNRIs), mental health referrals,
and psychotherapy are effective and approved by the United States (U.S.) Federal Drug
Administration (FDA) for the treatment of GAD (Abejuela & Osser, 2016; Craske & Bystritsky,
2017; Locke et al., 2015; National Institute for Health and Care Excellence [NICE], 2011;
NIMH, 2016). Healthcare providers who are thorough and consistent with implementation of
GAD screening and evidence-based treatment can efficiently and appropriately manage an
individual’s anxiety symptoms and improve his or her quality of life (Locke et al., 2015; NICE,
2011). The purpose of this quality improvement project was to implement an EBP anxiety
screening and treatment protocol for adults in a primary care clinic to increase early
identification and improve management of GAD. This chapter describes the outcomes of the
EBP quality improvement project and discusses its implications for nursing practice.
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Participant Demographics
A combined 673 adult, primary care electronic health records (EHRs)/charts (N = 673)
were reviewed. Of the 673 charts reviewed, 178 charts were included in the pre-implementation
retrospective (n = 81) and post-implementation prospective (n = 97) chart reviews because they
included a documented, active diagnosis and management for anxiety on the date of service for
the time which the chart was reviewed.
Expected Outcomes
The expected outcomes of the Doctor of Nursing Practice (DNP) EBP project are
outlined in four objectives.
Objectives
The purpose of this quality improvement project was to implement an EBP anxiety
screening and treatment protocol for adults in a primary care clinic to increase early
identification and improve management of GAD. Therefore, this project had the following
objectives:
1. Train five medical assistants on the administration of the GAD-7 assessment tool.
2. Implement an EBP anxiety screening and treatment protocol
3. Conduct retrospective and prospective chart reviews
4. Evaluate the anxiety screening and treatment protocol implementation process and
GAD identification and management outcomes.
In the context of this EBP project, implementation meant in an adult primary care clinic,
a practice change occurred by asking every patient, at every health visit, if they had felt anxious,
worried or fearful, more times than not, in the last 6 months, as the Diagnostic and Statistical
Manual 5th edition (DSM-V) diagnostic criteria recommends. Patients who answered “yes” and
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who agreed were screened with the GAD-7 screening tool; the score was tallied, the primary care
provider interpreted the score to an anxiety level and then used the anxiety level to assist in
prescribing EBP treatment, such as lifestyle modifications, SSRIs, SNRIs, mental health
referrals, psychotherapy, or combination therapy. In the context of this EBP project, improved
management meant the primary care provider prescribed treatment based on the GAD-7 anxiety
level according to an EBP protocol.
Evaluation of Outcomes
Descriptive statistics and Pearson’s r were utilized to analyze a total of 673 adult,
primary care EHRs/charts that were reviewed. Retrospective charts were reviewed for the
entirety of the months of March and April 2019. Retrospective charts were pre-implementation
of this EBP quality improvement project. Prospective charts reviewed for the entirety of the
months of June and July 2019 were post-implementation of the EBP quality improvement project
charts.
An evaluation of each of the project’s four objectives is discussed below.
Objective 1
Train five medical assistants on the administration of the GAD-7 screening tool. The
objective was not met. All MAs who were actively employed were trained; therefore, four
medical assistants were trained. One medical assistant was not trained because they resigned
from the position at the clinic.
Objective 2
Implement an EBP anxiety screening and treatment protocol. The objective was met. A
post-implementation prospective chart review revealed the EBP anxiety screening and treatment
protocol had been implemented, as evidenced by documentation in charts.
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Objective 3
Conduct retrospective and prospective chart reviews. The objective was met. A total of
673 charts were reviewed; 49.6% (n = 334) were retrospective charts and 50.4% (n = 339) were
prospective charts. Of the 673 charts, 178 charts were included in the retrospective and
prospective chart review data analysis because those charts had an active assessment and
treatment plan for GAD. Of the 178 charts that were included, 45.5% (n = 81) were
retrospective charts and 54.5% (n = 97) were prospective charts.
Gender of patient charts was not equally distributed and included 82.6% (n = 147) female
patients and 17.4% (n = 31) male patients (see Table 2).
Table 2
Gender and Age Distributions of Patient Charts with an Anxiety Diagnosis (n = 178)
Gender
Male
Female

n
31
147

%
18
82

The patient age ranges of charts reviewed was varied and as follows: 5.6% were 18-30
years old (n = 10), 22.5% were 31-45 years old (n = 40), 36.5% were 46-65 years old (n = 65),
29.2% were 66-79 years old (n = 52), and 6.2% were 80 years old or older (n = 11) (see Figure
1).
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Age Range Distribution of Patients
with Anxiety Dx.
(n = 178)
65
52
40

36.5
22.5

10

11

6.2

5.6

N
18-30

29.2

%
31-45

46-65

66-79

80 or older

Figure 1. Age range distribution of patients with anxiety diagnosis (n = 178).
Objective 4
Evaluate the anxiety screening and treatment protocol implementation process and GAD
identification and management outcomes. The objective was met. Post-implementation
prospective chart reviews revealed the process of the anxiety screening and treatment protocol
was implemented and GAD identification and management outcomes were measurable.
Two anxiety screening methods were identified in the chart reviews, an interview method
that consisted of a verbal assessment of symptoms based on the DSM-V diagnostic criteria and
the GAD-7 screening tool method, which quantified an anxiety score. The GAD-7 anxiety score
was interpreted to an anxiety level by the provider (Spitzer, Kroenke, Williams, & Lowe, 2006).
Regarding the anxiety score and level, a frequency distribution illuminated that preimplementation of the anxiety screening and treatment protocol, 0% of retrospective charts (n =
81) utilized a quantifiable anxiety screening tool (see Figure 2)’ therefore, 0% of retrospective
charts (n = 81) obtained an anxiety score/level. Analysis of the frequency of post-
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implementation utilization of the GAD-7 screening tool illuminated that 69.1% of prospective
charts (n = 67) utilized the GAD-7 screening tool to screen for GAD, which quantified an
anxiety level, whereas, 30.9% of prospective charts (n = 31) did not utilize the GAD-7 screening
tool to screen for GAD and did not quantify an anxiety level (see Figure 2).

Anxiety Screening Method
100
69.1
0
PRE-PROTOCOL
IMPLEMENTATION

30.9
POST-PROTOCOL
IMPLEMENTATION

% Obtained by Interview

% Quantified by GAD-7

Figure 2. Frequency of anxiety screening methods utilized pre-implementation and postimplementation.
An anxiety level should be obtained and utilized to select and monitor treatment for
GAD (Locke et al., 2015). Each chart’s treatment plan was manually reviewed by the project
implementer for correlation to anxiety level and EBP recommendations. Every chart was
assigned “yes” if the treatment had correlated an anxiety level to EBP treatment
recommendations and “no” if the treatment did not correlate an anxiety level to EBP treatment
recommendations. The anxiety level distribution of patients screened with the GAD-7 screening
tool was varied and as follows: 17.90% had a minimal anxiety level (n = 12), 22.40% had a mild
anxiety level (n = 15), 22.40% had a moderate anxiety level (n = 15), and 37.30% had a severe
anxiety level (n = 25) (see Figure 3).
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Anxiety Level Distribution of Patients Screened With
GAD-7 Screening Tool
37.30%

17.90%

Minimal

22.40%

Mild

22.40%

Moderate

Severe

Figure 3. Anxiety level distribution of patients screened with GAD-7 screening tool (n = 67).
During the beginning of the implementation phase, occasional utilization of the preimplementation professional interview method for GAD screening was noted. A frequency
distribution was calculated and converted to percentages of post-implementation prospective
charts that documented a prescribed EBP treatment based on a GAD-7 anxiety screening tool
level. Analysis illuminated 31.30% (n = 21) of post-implementation charts had a GAD-7
quantified anxiety level documented that correlated to EBP treatment and 68.70% (n = 46) of
post-implementation charts had a GAD-7 level that did not correlate to EBP treatment (see
Figure 4).

54

Correlation Between GAD Level and Prescribing EBP
Treatment
68.7
31.3
% GAD LEVEL CORRELATED TO
EBP TREATMENT

% GAD LEVEL DID NOT
CORRELATE TO EBP
TREATMENT

Figure 4. Correlation between GAD level and prescribing EBP treatment (n = 67).
The chart reviews revealed pre-existing treatment plans for GAD that were not based on a
GAD-7 quantified anxiety severity level. These pre-existing treatment plans included
benzodiazepines, SSRIs, SNRIs, or combination treatments. To maintain patient safety, these
types of medications must be titrated to discontinuation or effect (Furbish et al., 2017; Locke et
al., 2015). Therefore, the “change made to pre-existing treatment plan” variable was created to
identify and document any change that occurred to the treatment plan of a chart with a preexisting GAD treatment, yet this variable is not an indication that change was made in a positive
or negative direction to achieve EBP treatment based on anxiety level.
Of the post-implementation charts that documented use of the GAD-7 anxiety screening
tool (n = 67), 99% of those charts had a pre-existing GAD treatment plan. A frequency
distribution was calculated and converted to percentages for post-implementation charts that
utilized the GAD-7 screening tool and had a positive correlation between GAD level and
prescribing EBP treatment (n = 21), analysis revealed 90.5% (n = 19) had a change to the preexisting treatment plan and 9.5% (n = 2) did not have a change to the pre-existing treatment plan
(see Figure 5). This demonstrated that post-implementation prospective charts showed an
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increase in new EBP treatment plans added, or pre-existing treatment plans changed, based on
GAD-7 scores obtained.

Screened with GAD-7 Tool and had a Pre-Existing
Treatment Plan That was Changed to EBP
Treatment
90.5

9.5
% TREATMENT PLAN CHANGED

% TREATMENT PLAN NOT
CHANGED

Figure 5. Change made to pre-existing treatment plan (n = 21).
Pearson’s r was utilized to assess for statistical significance of post-implementation
charts utilizing the GAD-7 screening tool and whether GAD level correlated to prescribed EBP
treatment (n = 67) and found that correlation between GAD level and prescribing EBP treatment
was not statistically significant (see Table 3).
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Table 3
Pearson Correlation-GAD Level Correlated to Prescribed EBP Treatment (n = 67)

Score

Correlated Treatment

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

Score
1
67
-.122
.325
67

Correlated
Treatment
-.122
.325
67
1
67

**Correlation is significant at the 0.01 level (2-tailed)
Discussion
Strengths
This DNP EBP project showed a quantifiable anxiety screening tool for GAD was not
used in the primary care clinic before implementation of the EBP anxiety screening and
treatment protocol project. Best practices recommend correlating anxiety level to EBP treatment
(Locke et al., 2015; NICE, 2011). This project implemented a protocol that facilitated best
practices by screening and treating adults with GAD with a quantifiable screening tool (GAD-7)
to assist in prescribing treatment for GAD. Every patient who confirmed they had experienced
GAD symptoms over the past 6 months, as the DSM-V diagnostic criteria recommends, and
denied suicidal ideation, was provided the GAD-7 screening tool to quantify an anxiety level.
The primary care provider interpreted the anxiety severity level and selected an EBP treatment
that corresponded to the patient’s anxiety level. No patient answered “yes” to this question
during implementation.
The findings of this EBP project illuminated that post-implementation, this primary care
practice had a 69% increase of utilizing a quantifiable anxiety screening tool (GAD-7). Of those
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charts, 99% (n = 66) had a pre-existing GAD treatment plan. Additionally, the findings
demonstrated that 31.3% (n = 21) of post-implementation charts documented utilization of the
GAD-7 screening tool and an anxiety level that correlated to prescribed EBP treatment. Analysis
further revealed that 90.5% of those charts with a preexisting anxiety treatment plan also
documented that an algorithm-based change had been made to the preexisting treatment plan.
Implementing EBP ensures the provision of patient care excellence and improves patient
outcomes (Melnyk & Fineout-Overholt, 2015). There was a 69% increase in the utilization of a
quantifiable anxiety screening tool for adults in this primary care practice. A quantified anxiety
severity score should be utilized to prescribe EBP treatment for adults with GAD (Locke et al.,
2015). Additionally, the anxiety severity level can be utilized to track future patient progress and
be utilized for prescribing additional EBP treatment. Implementation of best practices for GAD
screening and treatment in primary care improves the quality of life in adults with GAD (Locke
et al., 2015). This EBP project was clinically significant because it screened primary care
patients for anxiety, identified patients who were suffering with anxiety and quantified their
severity level, and provided the primary care provider with a best practices algorithm to
prescribe anxiety treatment plans based on patients’ anxiety severity level.
On the premise that EBP improves patient outcomes, future analysis of the clinical
findings that analyze the correlation of anxiety level to EBP treatment, at this primary care site,
may determine that patients are receiving EBP treatment that is appropriate for their anxiety level
and are experiencing improved outcomes. The primary care provider and medical assistants
were enthusiastic and supportive and implemented the systems change for EBP screening and
treatment for adults with GAD at the clinical practice site.

58
Limitations
This project had several limitations. The anxiety screening and treatment protocol was
not consistently implemented at the beginning of the implementation phase because one MA did
not consistently provide patients with the GAD-7 screening tool when indicated. Consequently,
full implementation of screening for GAD with a quantifiable screening tool was not achieved.
Therefore, only 69% (n = 67) of prospective charts documented that the patient was screened
with the GAD-7 screening tool to quantify an anxiety level. However, once recognized that the
MA was not screening all patients according to the anxiety screening and treatment protocol, the
primary care provider intervened and informed the MA to follow the anxiety screening protocol
and provide the GAD-7 screening tool to patients when indicated.
As a result of the slow adoption of the tool at the beginning of the project, only 67 of the
97 post-implementation phase charts that contained a treatment plan for GAD could be analyzed
for correlation to EBP treatment prescribed based on a quantified level of anxiety level. Another
significant limitation noted related to preexisting treatment plans for GAD, such as
benzodiazepines, SSRIs, SNRIs or combination treatments. To maintain patient safety, these
types of medications could not be immediately changed to align with EBP protocol guidelines, as
they must be titrated to discontinuation or effect (Furbish et al., 2017; Locke et al., 2015). To
account for this, a “new intervention” variable was created to document any change that occurred
to the treatment plan of a chart with pre-existing GAD treatment. However, the new intervention
variable is not an indication that change was made in a positive or negative direction to achieve
EBP treatment based on anxiety level. Hence, it was unclear whether a gap still exists for
correlating anxiety severity level to EBP treatment. In addition, the primary care provider found
that providing timely and accessible mental health services was difficult for a majority of
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patients with non-private health insurance; nonetheless, patients were provided with the contact
information for mental health resources, such as the Substance Abuse and Mental Health
Services Administration’s (SAMHSA) National Helpline that provides free, 24/7 access to
mental health referrals and information.
Implications for Nursing Practice
An EBP project implemented a systematic change at a primary care clinic in south
Florida that included screening patients for anxiety with a valid and reliable evidence-based tool
that identifies and quantifies GAD severity level and prescribing GAD treatment according to an
EBP protocol.
The EBP quality improvement project can be used to advocate for the routine use of an
anxiety screening tool in all primary care settings in order to align with best practices.
Additionally, the EBP quality improvement project can be used to advocate for compliance with
implementation of appropriate EBP GAD treatments based on GAD-7 quantified anxiety level
severity. The EBP project should be adopted as a standard of care. All patients, at every visit,
should be asked the basic questions of GAD diagnostic criteria. Every patient who confirms they
have experienced GAD symptoms for 6 months, as the DSM-V diagnostic criteria recommends,
should be provided the GAD-7 screening tool to quantify an anxiety level (Locke et al., 2015).
Primary care providers should interpret patients’ GAD-7 quantified anxiety level and select
corresponding EBP recommendations for treatment.
The EBP project illuminated an EBP standard of care for prescribing benzodiazepines for
GAD. Benzodiazepines should only be used short term for severe anxiety, if necessary, to
augment treatment. Benzodiazepines should only be used long-term, on a strict as needed basis,
if the provider has established that the patient experiences panic attacks (Locke et al., 2015;
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NICE, 2011). If a patient experiences panic attacks, the provider should consider quantifying the
monthly number of panic episodes and only prescribe low-dose benzodiazepines for the exact
number of episodes expected monthly, and as needed follow-up should ensue.
The American Association of Colleges of Nursing’s (AACN; 2006) Essentials of
Doctoral Education for Advanced Nursing Practice, commonly known as the DNP Essentials,
describes eight pertinent components of DNP education. According to the AACN, the curricula
of DNP programs must prompt the DNP candidate to acquire knowledge and demonstrate
competence in the following eight DNP Essentials: Scientific Underpinnings for Practice,
Organizational and Systems Leadership for Quality Improvement, Clinical Scholarship and
Analytical Methods for Evidence-Based Practice, Information Systems Technology and Patient
Care Technology for the Improvement and Transformation of Health Care, Health Care Policy
for Advocacy in Health Care, Inter-professional Collaboration for Improving Patient and
Population Health Outcomes, Clinical Prevention and Population Health for Improving the
Nation’s Health, and Advanced Nursing Practice. The project implementer demonstrated
competency in the AACN’s eight DNP Essentials by implementing the EBP project
Implementation of an EBP Anxiety and Treatment Protocol in Primary Care.
Scientific Underpinnings for Practice
The AACN (2006) described scientific underpinnings for practice as utilizing theory and
evidence-based practice as a foundation to guide practice. The Institute for Healthcare
Improvement (2019) suggested the use of a systems model, such as the Plan-Do-Study-Act
(PDSA), for developing and testing processes, with a goal of sustainability. An extensive
literature review and a clinical practice assessment of GAD screening and treatment practices in
a primary care practice was conducted. Lack of use of a uniform, quantifiable screening method
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for GAD was noted (Olarui et al., 2015; Weisberg et al., 2014). EBP recommends utilizing an
anxiety level to prescribe treatment for GAD in adults (Locke et al., 2015; NICE, 2011). Best
practices for prescribing GAD treatment were also lacking (Bachhuber et al., 2016; Carico et al.,
2018; Weisberg et al., 2014). Utilizing the PDSA model, a DNP EBP quality improvement
protocol was developed that implemented current and tested best practices for screening and
treating adults with GAD in primary care.
The GAD-7 (see Appendix C) is a well-tested and reliable tool, specific to screening for
GAD in primary care (Jordan et al., 2017; Spitzer et al., 2006). Current clinical practice
guidelines suggest screening adults for GAD by utilizing a quantifiable anxiety screening tool,
such as the GAD-7 (Locke et al., 2015). Further, the evidence has demonstrated that
implementation of EBP treatment such as lifestyle modifications, SSRIs, SNRIs, mental health
referrals, and psychotherapy, correlated to the individual’s anxiety level, decreases GAD
symptoms, and can increase the quality of life in sufferers (Locke et al., 2015; NICE, 2011).
Organizational and Systems Leadership
The AACN (2006) described organizational and systems leadership as sensitivity to
delivery of leadership to diverse organizational cultures and patient populations. A leadership
style that is welcoming and adaptable to healthcare changes is a pertinent factor of success,
because healthcare is evolutionary, and adaptions and modification are a necessity for success
(Hargett et al., 2017).
This EBP project met the needs of the diverse organizational culture of this project’s
setting. During the developmental phase of this EBP, close observations of organizational
practices and workflow were made. Observations noted were: individual tasks of the clinical
employees, a general timeline of completing the tasks, and the ability of clinic personnel to adapt
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and participate in a team player approach. Acknowledging employees’ strengths and weaknesses
and how to best assist each employee to successful implementation of this project required
leadership. To maintain employee tactfulness and cooperation, concise communication and easy
access to the GAD-7 screening tool was delivered to each employee. The GAD-7 screening tool
is available in multiple languages and easily accessible (Mills et al., 2014). This EBP quality
improvement project was developed to safely and successfully implement change in the way that
patients were screened and treated for GAD, with a goal of ensuring EBPs and optimal outcomes
for a better quality of life.
Sensitivity to patient populations was also met during this EBP project. This EBP project
was a quality improvement system change comprised of inter-professional collaboration,
individualized care, and educating clinical employees about best GAD screening practices. From
the GAD-7 screening tool to the selection of an evidence-based treatment, this project educated
patients about their anxiety disorder and how to improve their quality of life through
individualized treatment. Upon interview, numerous patients misunderstood GAD and, in fact,
described it as a panic attack. Individuals with GAD can suffer panic attacks, but they are not
the same disorder (Locke et al., 2015). It appeared these patients who misinterpreted their GAD
for a panic disorder tended to be the same patients who used benzodiazepines daily. Educating
patients about GAD, their GAD-7 score, and appropriate EBP treatment helps them understand
their disease process and the most appropriate treatment for symptom management.
The findings of the DNP EBP project can help shape leadership in healthcare because it
contributes to evidence that the process of implementing a quantifiable GAD screening method
can assist in prescribing EBP treatment and achieving the outcome of early identification and
improved management of GAD in adults.
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Clinical Scholarship and Analytic Methods
The AACN (2006) defines clinical scholarship and analytic methods as an initiative to
pursue discovery and problem solve complex situations through knowledge and disseminating
research; therefore, adopting and adding EBP among disciplines to improve healthcare outcomes
is essential. The EBP project demonstrated clinical scholarship by discovering that screening
and treatment practices for adults with GAD in primary care were lacking, not uniform, and/or
inconsistent. Through analytic methods, the EBP project reviewed current literature and research
to discover current, best practices for screening and treating adults with GAD. A quality
improvement process was then designed and implemented utilizing a well-tested, valid, and
reliable GAD screening tool and EBP treatment with the intent to increase early identification
and improve management of adults with GAD in a primary care clinic.
Information Systems/Patient Care Technology
According to the AACN (2006), information systems and patient care technology
requires the DNP to access and utilize technology. Healthcare technology is classified as soft,
hard, or soft-hard. Soft technology consists of triage, professional-patient encounters, and
rapport. Hard technology consists of exams, treatments, organizing information, and
instruments. Lastly, soft-hard technology refers to the knowledge acquired from the healthcare
team (Feitosa et al., 2015). This EBP project utilized soft, hard, and soft-hard information
technologies and technological databases. The GAD-7 is a measurable tool that allowed the
clinical staff, patients, and inter-professional collaborators to measure, communicate, and
implement individualized treatment plans based on severity of anxiety. Further, this EBP project
required documentation of the GAD-7 score/level and treatment plan to be recorded in the EHR
as a baseline to be easily accessed for reassessment purposes in the future treatment of the
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patient. This process contributed knowledge about the individual’s GAD baseline level that can
be referred to for future assessment and treatment. The development of this EBP project
required utilization of information databases to search, find, and disseminate evidence and to
compose an EBP protocol for screening and treating anxiety. The DNP EBP project also utilized
technology for analysis of data. The data analysis software used were Microsoft Excel and
International Business Machines Statistical Package for the Social Sciences (IBM SPSS).
Microsoft PowerPoint was utilized to train the medical assistants.
Healthcare Policy for Advocacy in Healthcare
According to the AACN (2006), the DNP should be engaged in the undertaking of policy
development, political activism, and advocacy for an array of healthcare issues with emphasis on
cultural sensitivity, healthcare access, healthcare disparities, affordable care, social justice, and
quality care. The DNP student advocated for timely diagnosis and quality GAD treatment for
adults. Anxiety often precedes depression, and the physical and social consequences of GAD are
cumbersome and threaten the quality of life in sufferers (Galyamina, Kovalenko, Smagin, &
Kudryavtseva, 2017; Locke et al., 2015). In response to the quality of life consequences of
uncontrolled depression, the United States (U.S.) Preventive Services Task Force [USPSTF]
(2016) issued a final recommendation of screening all adults for depression, with a uniform
screening tool, to ensure early identification and prompt treatment to increase the quality of life
in adults with depression. The DNP student advocated for adoption of a national
recommendation to routinely screen all adults for GAD with a uniform and anxiety level
quantifiable screening tool, at least annually, to increase early identification and prompt EBP
treatment for adults with GAD.
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Interprofessional and Intraprofessional Collaboration
Collaborative efforts are needed to provide comprehensive healthcare (AACN, 2006).
Interprofessional and intraprofessional are two forms of collaboration. Interprofessional
collaboration occurs when members of at least two different healthcare professions agree to work
closely to goal set, share responsibility and accountability, and seek successful results (Green &
Johnson, 2015). Interprofessional collaboration also occurs when different types of healthcare
members provide delivery of healthcare services across the healthcare spectrum. This type of
collaboration is a crucial component to ensuring the most optimal healthcare outcomes for
patients (Green & Johnson, 2015). Intraprofessional collaboration functions similarly; however,
it occurs among members of the same professional discipline (Meijer, Groot, Westerlaken, &
Damoiseaux, 2016).
Interprofessional and intraprofessional collaboration was a vital component of the
successful implementation of this EBP project. For this EBP project, the primary care provider
implemented clinical recommendations for screening and treating GAD to select an
individualized plan for each patient. In part, best practices for treating GAD include mental
health referrals and psychotherapy (Locke et al., 2015; NICE, 2011). The EBP anxiety screening
and treatment protocol included the utilization of mental health services for GAD treatment.
Intraprofessional collaboration was supported during this project, which incorporated
collaborative efforts among the medical assistants to consistently deliver the GAD-7 screening
tool to patients.
Clinical Prevention and Population Health
According to the AACN (2006), clinical prevention and population health is intended to
improve the nation’s health outcomes. This EBP project was designed to increase the early
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identification of GAD and to enhance compliance with EBP treatment recommendations for
GAD in primary care. Often, individuals with GAD present to their primary care providers,
despite the reason for their health visit (Goldberg et al., 2016; Roberge et al., 2015; Weisberg et
al., 2014; Wiegner et al., 2015). This provides an opportunity for a diagnosis of GAD to be
captured promptly. Prompt GAD screening can lead to timely treatment and improve patient
outcomes (Locke et al., 2015). Utilization of an anxiety screening tool that quantifies level of
severity helps the provider to prescribe appropriate, best practice treatments based on anxiety
severity for adults with GAD. Implementation of an anxiety screening and treatment protocol in
primary care for adults with GAD can decrease its consequences and improve quality of life in
sufferers (Locke et al., 2015; Roberge et al., 2015).
Advanced Nursing Practice
The AACN (2006) defines advanced nursing practices as using advanced clinical
judgment, accountability, and systems thinking to comprehensively conduct an assessment of
wellness and illness parameters in complex situations; design, implement and evaluate practice
changes; and provide guidance and education during complex and/or situational changes.
Advanced nursing practice was demonstrated by developing, implementing, and evaluating an
EBP quality improvement anxiety screening and treatment protocol project for primary care
adults with GAD.
Final Conclusions
The purpose of this quality improvement project was to implement an EBP anxiety
screening and treatment protocol for adult patients in a primary care clinic to increase early
identification and improve management of GAD. Findings were clinically significant and
demonstrated 69.07% of post-implementation prospective charts utilized the GAD-7 screening
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tool to screen for, and quantify severity level of, GAD that could be utilized to prescribe EBP,
which is best care recommendations for treatment for adults with GAD in primary care. Further,
the findings demonstrated that post-implementation EHR’s that documented utilization of the
GAD-7 screening tool were able to be analyzed for correlation to EBP treatment. As a result,
these charts can also be analyzed and utilized to justify that the primary care provider is
practicing according to clinical guideline recommendations. On the premise that EBP improves
patient outcomes, future analysis of the clinical findings that analyze the correlation of anxiety
level to EBP treatment, at this primary care site, may determine that patients are receiving EBP
treatment that is appropriate to their anxiety level and are experiencing improved outcomes.
There was an increase of new or changed anxiety treatment to preexisting GAD treatment plans
noted during the implementation of this project, in comparison to retrospective charts reviewed.
Further studies are necessary to determine if the changes made to the preexisting treatment plans
will eventually result in a treatment plan that aligns with EBP treatment in adults with GAD.
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Appendix A
IRB Approval Letter

MEMORANDUM

To:

Danielle Garcia

From:

Vanessa A Johnson, Ph.D.,
Center Representative, Institutional Review Board

Date:

May 14, 2019

Re:

IRB #: 2019-285; Title, “Implementation of an EBP Anxiety Screening and
Treatment Protocol in Primary Care Practice”

I have reviewed the above-referenced research protocol at the center level. Based on
the information provided, I have determined that this study is exempt from further IRB
review under 45 CFR 46.101(b) ( Exempt 2: Interviews, surveys, focus groups,
observations of public behavior, and other similar methodologies). You may
proceed with your study as described to the IRB. As principal investigator, you must
adhere to the following requirements:
1)

CONSENT: If recruitment procedures include consent forms, they must be
obtained in such a manner that they are clearly understood by the subjects and
the process affords subjects the opportunity to ask questions, obtain detailed
answers from those directly involved in the research, and have sufficient time to
consider their participation after they have been provided this information. The
subjects must be given a copy of the signed consent document, and a copy must
be placed in a secure file separate from de-identified participant information.
Record of informed consent must be retained for a minimum of three years from
the conclusion of the study.

2)

ADVERSE EVENTS/UNANTICIPATED PROBLEMS: The principal investigator is required to
notify the IRB chair and me (954-262-5369 and Vanessa A Johnson, Ph.D., respectively) of any
adverse reactions or unanticipated events that may develop as a result of this study. Reactions
or events may include, but are not limited to, injury, depression as a result of participation in the
study, life-threatening situation, death, or loss of confidentiality/anonymity of subject. Approval
may be withdrawn if the problem is serious.

3)

AMENDMENTS: Any changes in the study (e.g., procedures, number or types of subjects,
consent forms, investigators, etc.) must be approved by the IRB prior to implementation. Please
be advised that changes in a study may require further review depending on the nature of the
change. Please contact me with any questions regarding amendments or changes to your study.
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The NSU IRB is in compliance with the requirements for the protection of human subjects prescribed in
Part 46 of Title 45 of the Code of Federal Regulations (45 CFR 46) revised June 18, 1991.

Cc:

Kelly Henson-Evertz
Vanessa A Johnson, Ph.D.
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Appendix B
Clinical Site Approval Letter

SITE APPROVAL LETTER
Nova Southeastern University 3301 College Avenue
Fort Lauderdale, FL 33314-7796
Subject: Site Approval Letter
To whom it may concern:
This letter acknowledges that I have received and reviewed a request by Danielle E. Garcia,
MSN, APRN, FNP-C to conduct a research project entitled "Implementation of an EBP Anxiety
Screening and Treatment Protocol in Primary Care Practice" at Primary Care Associates and I
approve of this research to be conducted at our facility.
When the researcher receives approval for his/her research project from the Nova Southeastern
University's Institutional Review Board/NSU IRB, I agree to provide access for the approved
research project. If we have any concerns or need additional information, we will contact the
Nova Southeastern University's IRB at (954) 262-5369 orirb@nova.edu.
Sincerely,
Yohanna Deno, MD
Medical Director/ Medical Doctor
5-13-19
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Appendix C
Generalized Anxiety Disorder 7-item (GAD-7)

PCP validates GAD-7 score
and interprets anxiety level

MA collects GAD-7 tool from
patient, tallies score, records
score in EHR, places GAD-7
on chart

MA asks, “Are you having
thoughts of killing yourself
right now?”

MA retrieves GAD-7 tool and
requests patient complete
questionnaire

Yes

Patient is not left alone. STAT
mental health intervention is
implemented

No

PCP discusses anxiety
score/level and significance with
patient, and
recommends/implements
treatment plan

*Medical Assistant (MA)
*Primary Care Provider (PCP)

Score >4: PCP discusses anxiety
score with patient, assesses for
underlying conditions, performs
full physical assessment and
review of systems

Yes

On intake, Medical Assistant (MA)
asks all adult patients 18 years and
older “Have you experienced
feelings of worry, fear, or mental
unease over the past six-months?”

Anxiety Screening and Treatment Protocol

Appendix D

No further
anxiety
screening
required

See
Appendix
A
continued
page 2
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PCP documents anxiety
level and treatment plan
into EHR

5-9 (mild):
Provide patient education and
active listening, consider patient’s
treatment requests, recommend
lifestyle modifications, offer
relaxation techniques
10-14 (moderate):
Provide recommendations for mild
anxiety, consider history, allergies, and
patient preference, offer the following:
CBT
(via mental health provider)
or
SSRI
or
SNRI
or
combination CBT and either: SSRI or
SNRI
6-week follow-up

15+ (severe):
Provide recommendations for mild
anxiety, provide referral and contact
information of mental health specialist
and facilitate scheduling appointment,
6-week follow-up and PRN, ensure
follow-up appointment is scheduled,
provide contact info and educate
patient to make immediate contact
with PCP for increasing
severity/frequency of symptoms

*This EBP protocol for anxiety treatment was adapted/modified from Community Care of North Carolina anxiety treatment
recommendations.

0-4 (minimal):
follow-up at
next regular
visit

In collaboration with patient, PCP
selects treatment based on anxiety level
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Appendix E
Statement of Use
Introduction
In the Fall of 2017, in response to requests from our CCNC Primary Care Providers, a
Community Care of North Carolina (CCNC) workgroup formed to create a resource guide
designed to assist primary care practitioners in screening and treating adult anxiety in the
primary care setting. This workgroup was comprised of Network Psychiatrists, Network
Pharmacists, Network Behavioral Health Coordinators, the CCNC Central Office Behavioral
Health Team, and physician representatives from area medical practices.
This resource guide is designed to assist busy primary care practitioners in accessing practical,
evidence-based tools to help them successfully treat anxiety in adults. It includes algorithms to
aid in the initial assessment and corresponding treatment approach of adult generalized anxiety
disorder (GAD) and panic disorder, screening tools, a medication guide, and billing and coding
guidance. In addition, the resource guide highlights anxiety-depression comorbidity prevalence,
and gives suggestions for anxiety-driven referral language and grounding (breathing) techniques
that can be performed by both the patient or the practitioner.
Our hope is that this resource guide proves useful, and we greatly look forward to continuing to
work together on achieving the highest attainable levels of patient care across our wonderful
state of North Carolina.
If you have any questions, or would like assistance in connecting with your local CCNC
Network and its resources, please contact a member of the Central Office Behavioral Health
Team: (Current as of Summer 2018)
Andrew Clendenin, MSW
Jennie Byrne, MD, PhD
Nicole Laramee, MPH
Director aclendenin@communitycarenc.org
Deputy Chief Medical Officer jbyrne@communitycarenc.org
Program Manager nlaramee@communitycarenc.org

